quinazolines has been researched along with deoxycytidine in 507 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (2.17) | 18.2507 |
| 2000's | 182 (35.90) | 29.6817 |
| 2010's | 307 (60.55) | 24.3611 |
| 2020's | 7 (1.38) | 2.80 |
| Authors | Studies |
|---|---|
| Verweij, J | 1 |
| Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D | 1 |
| Hanauske, AR | 1 |
| Armand, JP | 1 |
| Kinsella, AR; Smith, D | 1 |
| McCann, J | 1 |
| Punt, CJ | 1 |
| Adjei, AA | 1 |
| Cao, S; Rustum, YM | 1 |
| Bekradda, M; Cvitkovic, E | 1 |
| Adenis, A; Conroy, T; Paillot, B | 1 |
| Hoff, PM; Pazdur, R; Royce, ME | 1 |
| Firby, PS; Hedley, DW; Moore, MJ; Rauchwerger, DR | 1 |
| Bregman, D; Manalo, J; Mani, S | 1 |
| Cunningham, D; James, RD | 1 |
| Reimer, P; Rückle-Lanz, H | 1 |
| Boige, V; Ducreux, M; Taïeb, J | 1 |
| Gallant, JE | 1 |
| D'Orazio, AI; Gambill, BD | 1 |
| Fishman, AD; Wadler, S | 1 |
| Chu, E; Copur, S; DeGrendele, HC; Jain, VK; Lee, D; Maung, K; Schilsky, R | 1 |
| Hedley, DW; Ng, SS; Nicklee, T; Tsao, MS | 1 |
| Ruffié, P | 1 |
| Vogelzang, NJ | 1 |
| Aebi, S; Borner, MM; Büchler, MW; Friess, H; Kralidis, E | 1 |
| Depisch, D; Haider, K; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H; Verena Kornek, G | 1 |
| Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U | 1 |
| Gallagher, N; Smith, D | 1 |
| Herchenhorn, D; Rabinowits, G; Rabinowits, M; Torres, W; Weatge, D | 1 |
| Ciccolini, J; Dubreuil, A; Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Magné, N; Marchetti, S; Milano, G; Renée, N; Tiffon, C | 1 |
| Cats, A | 1 |
| Averbuch, SD; Fandi, A; Gatzemeier, U; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Pluzanska, A; Rennie, P; Rosell, R; Scagliotti, G; Schiller, JH; Von Pawel, J; Wolf, MK | 1 |
| Alfonso, R; Averbuch, S; Fandi, A; Giaccone, G; González-Larriba, JL; Martens, M; Peters, GJ; Smit, EF; Smith, R; van der Vijgh, WJ; van Oosterom, AT | 1 |
| Adames, V; Beck, G; Birnboeck, H; Gand, L; Higgins, B; Hoffmann, G; Kolinsky, K; Linn, M; Rashed, M; Smith, M; Wheeldon, E | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Cao, S; Durrani, FA; Rustum, YM | 1 |
| Bocci, G; Danesi, R; Di Paolo, A | 1 |
| Arends, JJ; de Jong, RS; Leys, MB; Nortier, JW; Sleeboom, HP; Smit, JM; Ten Bokkel Huinink, D; Tesselaar, ME | 1 |
| Carminati, O; De Giorgi, U; Kopf, B; Marangolo, M; Rosti, G; Zago, S | 1 |
| Akita, H | 1 |
| Klabatsa, A; Steele, JP | 1 |
| Normanno, N | 1 |
| Caenepeel, P; Demols, A; Houbiers, G; Leleux, A; Peeters, M; Polus, M; Van Cutsem, E; Van Laethem, JL; Van Maele, P; Vermaut, RR; Verslype, C | 1 |
| Kaplow, R | 1 |
| du Manoir, J; Francia, G; Hicklin, DJ; Kerbel, RS; Ma, L; Rak, J; Viloria-Petit, A | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Lutz, MP | 1 |
| Cheng, AL; Shen, YC; Wan, JP; Yeh, KH; Yeh, SH | 1 |
| Bartolini, S; Cappuzzo, F; Crinò, L; Finocchiaro, G; Metro, G; Toschi, L; Trisolini, R | 1 |
| Burris, HA | 1 |
| Edelman, MJ | 1 |
| Ko, AH; Tempero, MA | 1 |
| Brown, ER; Shepherd, FA | 1 |
| Horio, Y; Mitsudomi, T; Shimizu, J | 1 |
| Akerman, P; Barnett, JM; Cioffi, W; Cruff, D; Dipetrillo, T; Iannitti, D; Kennedy, T; Maia-Acuna, C; Martel, D; Miner, T; Remis, M; Safran, H | 1 |
| Moore, MJ | 1 |
| Ouchi, KF; Sekiguchi, F; Tanaka, Y; Yanagisawa, M | 1 |
| Chun, PY; Davis, MA; Feng, FY; Lawrence, TS; Nyati, MK; Scheurer, AM | 1 |
| Bendell, JC; Blobe, GC; Clary, BM; Czito, BG; Fernando, NH; Honeycutt, W; Hurwitz, HI; Ludwig, KA; Mantyh, CR; Morse, MA; Pappas, TN; Tyler, DS; Willett, CG; Yu, D | 1 |
| Aprile, G; Balzano, G; Bonetto, E; Brandes, AA; Cordio, S; Dell'Oro, S; Di Carlo, V; Fugazza, C; Luppi, G; Milandri, C; Nicoletti, R; Pasetto, L; Passoni, P; Piemonti, L; Reni, M; Zerbi, A | 1 |
| Hennemann, B | 1 |
| Chen, YM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| de Jager, J; Stebbing, J | 1 |
| Garcia-Carbonero, R; Paz-Ares, L | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX | 1 |
| Laurie, SA; Licitra, L | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Ho, C; Lara, PN; Mack, P | 1 |
| Eng, C; Shalan, N | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Kim, DW; Kim, TY; Lee, KH; Oh, DY | 1 |
| Maekawa, M; Okusaka, T; Yamada, T | 1 |
| Augé, JM; Ayuso, C; Cajal, R; Conill, C; Fernández-Cruz, L; Gallego, R; Gascón, P; Ginès, A; Marmol, M; Martin-Richard, M; Maurel, J; Miquel, R; Nadal, C; Navarro, S; Petriz, L; Sánchez, M | 1 |
| Curtiss, FR | 1 |
| Cognetti, F; Di Segni, S; Fontana, A; Gelibter, AJ; Labianca, R; Lonardi, S; Loupakis, F | 1 |
| Abbruzzese, J; Ali, IF; Ali, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 1 |
| Bianco, C; Ciardiello, F; Cionini, L; Danesi, R; de Liguoro, M; Del Tacca, M; Eckhardt, G; Giovannetti, E; Mey, V; Nannizzi, S; Pasqualetti, F; Raben, D; Ricciardi, S; Tortora, G; Troiani, T | 1 |
| Dragovich, T; Hage, G; Hamilton, M; Huberman, M; Nadler, P; Patnaik, A; Rowinsky, EK; Von Hoff, DD; Wolf, J; Wood, D | 1 |
| Berger, M; Cameron, D; Campone, M; Chan, A; Chan, S; Crown, J; Davidson, N; Forster, J; Geyer, CE; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Oliva, C; Pienkowski, T; Romieu, CG; Rubin, SD; Skarlos, D; Stein, S | 1 |
| Muss, HB | 1 |
| García-Foncillas, J; Gil, C; Monreal, I; Rodríguez, J; Salgado, J; Zabalegui, N | 1 |
| Boye, K; Bras-Gonçalves, RA; Chapelier, A; de Cremoux, P; Defrance, R; Judde, JG; Livartowski, A; Poupon, MF; Rebucci, M; Tran-Perennou, C; Vogt, N | 1 |
| Hanada, M; Noguchi, T; Yamaoka, T | 1 |
| Griffiths, TR; Kriajevska, M; McHugh, LA; Mellon, JK | 1 |
| Sonpavde, G | 1 |
| Chen, YM; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Barge, A; Bruns, CJ; Conrad, C; Geissler, EK; Guba, M; Ischenko, I; Jauch, KW; Köhl, G; Ryan, AJ; Wedge, SR; Wiegand, U; Yezhelyev, M | 1 |
| Boeck, S; Heinemann, V; Moosmann, N; Stemmler, HJ | 1 |
| Kindler, HL | 1 |
| Yoneda, S | 1 |
| Chun, PY; Davis, MA; Feng, FY; Lawrence, TS; Li, X; Lopez, CA; Normolle, DP; Nyati, MK; Varambally, S | 1 |
| De Rosa, F; Gatzemeier, U; Janaskova, T; Karnicka-Mlodkowski, H; Kaukel, E; Manikhas, GM; Milanowski, J; Pesek, M; Pluzanska, A; Ramlau, R; Roubec, J; Serwatowski, P; Strausz, J; Szczesna, A; Vansteenkiste, J; Von Pawel, J | 1 |
| Boige, V; Ducreux, M; Malka, D | 1 |
| Au, HJ; Campos, D; Clark, G; Ding, K; Figer, A; Gallinger, S; Goldstein, D; Hamm, J; Hecht, JR; Lim, R; Moore, MJ; Murawa, P; Parulekar, W; Ptasynski, M; Voskoglou-Nomikos, T; Walde, D; Wolff, RA | 1 |
| Burtness, B | 1 |
| Bareschino, M; Ciardiello, F; Gridelli, C; Maione, P; Mongillo, F; Rossi, A | 1 |
| Cagnoni, PJ; Clark, G; Nagrani, T; Wacker, B; Weinberg, J; Witt, K | 1 |
| Furuse, J; Ishii, H; Nakachi, K; Shimizu, S; Suzuki, E | 1 |
| Christophylakis, C; Georgoulias, V; Ignatiadis, M; Kalbakis, K; Kotsakis, A; Polyzos, A; Potamianou, A; Stathopoulos, GP; Tselepatiotis, E; Vamvakas, L | 1 |
| Cognetti, F; Di Costanzo, F; Ferraresi, V; Gabriele, A; Gamucci, T; Gasperoni, S; Gelibter, AJ; Giannarelli, D; Nuzzo, C; Pollera, CF; Signorelli, C; Zeuli, M | 1 |
| Jones, DV; Klementich, FJ; Ravindranathan, M | 1 |
| Brand, RE; Carneiro, BA; Fine, E; Khandekar, JD; Knop, RH; Locker, GY; Uhlig, W | 1 |
| Kibble, A | 1 |
| Cameron, D | 1 |
| Arya, N; Chu, QS; Curtright, J; de Bono, J; Fleming, RA; Ho, PT; Koch, KM; Pandite, L; Rowinsky, EK; Schwartz, G; Smith, DA; Versola, MJ | 1 |
| Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C | 1 |
| Capanu, M; Duffy, A; Kelsen, DP; Kortmansky, J; Minsky, B; O'Reilly, EM; Puleio, S; Saltz, L; Schwartz, GK | 1 |
| Goldstein, M; Miksad, RA; Schnipper, L | 1 |
| Bajorin, D; Halabi, S; Philips, GK; Sanford, BL; Small, EJ | 2 |
| Alexandru, A; Dediu, M; Gal, C; Median, D; Vremes, G | 1 |
| Luo, Y; Walla, M; Wyatt, MD | 1 |
| Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX | 1 |
| Gemma, A; Kudoh, S; Matsuda, K; Minegishi, Y; Nara, M; Noro, R; Okano, T; Shibuya, M; Takemura, A; Yoshimura, A | 1 |
| Beale, P; Brennscheidt, U; Bugat, R; Clarke, S; Delord, JP; Fettner, SH; Feyereislova, A; Rakhit, A; Van Cutsem, E; Verslype, C | 1 |
| Miller, JD | 1 |
| Betticher, DC; Bihl, M; Bubendorf, L; D'Addario, G; Jost, L; Lerch, S; Mach, N; Mayer, M; Pless, M; Rauch, D; Ribi, K; Stahel, R; Stupp, R; Tapia, C; Widmer, L | 1 |
| Philip, PA | 1 |
| Cameron, D; Campone, M; Casey, M; Chan, A; Chan, S; Crown, J; Davidson, N; Geyer, CE; Gorbounova, V; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Newstat, B; Oliva, C; Paoletti, P; Pienkowski, T; Press, M; Raats, JI; Romieu, CG; Roychowdhury, D; Rubin, S; Skarlos, D; Stein, S; Viens, P | 1 |
| Boyle, F; Burris, HA; Byrne, J; Chan, S; Crown, JP; Jones, S; Koehler, M; Newstat, BO; Oliva, C; Parikh, R; Preston, A | 1 |
| Alonso, V; Bovio, H; Colomer, R; Cortés-Funes, H; Escudero, P; García-Carbonero, R; Grávalos, C; Jimeno, A; Juez, I; Sevilla, I; Vega-Villegas, ME | 1 |
| Johnson, JR; Justice, R; Pazdur, R; Senderowicz, AM; Sridhara, R; Zimmerman, P | 1 |
| Baselga, J; De Rosa, F; Fettner, S; Jones, R; Rakhit, A; Trigo, JM; Twelves, C; Wright, T | 1 |
| Belani, C; Ramalingam, S | 1 |
| Epstein, RJ; Leung, TW | 1 |
| Adam, P; Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Quinkler, M; Ritte, C; Ritter, C; Strasburger, C; Wortmann, S | 1 |
| Blumenfeld, M; Farrar, W; Landon, MB; Pant, S; Shapiro, CL | 1 |
| Kim, YT | 1 |
| Barutca, S; Bolaman, Z; Kadikoylu, G; Meydan, N; Yavasoglu, I | 1 |
| Burris, H; Rocha-Lima, C | 1 |
| Chua, YJ; Zalcberg, JR | 1 |
| Van Laethem, JL | 1 |
| Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D | 1 |
| Saif, MW | 1 |
| Mukesh, M; Murray, P | 1 |
| Dean-Colomb, W; Esteva, FJ | 1 |
| Rocha-Lima, CM | 1 |
| Gillani, JA; Iqbal, M; Khan, A; Nasreen, S; Samad, A | 1 |
| Krop, IE; Winer, EP | 1 |
| Cobleigh, MA; Dickler, MN; Klein, PM; Miller, KD; Winer, EP | 1 |
| Danese, MD; Lin, CY; Lubeck, D; Northridge, K; O'Connor, P; Reyes, C | 1 |
| Rocha-Lima, C; Vulfovich, M | 1 |
| Cameron, DA; Stein, S | 1 |
| Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW | 1 |
| Butts, C; Ciardiello, F; Feld, R; Gallo, C; Gridelli, C; Perrone, F | 1 |
| Paoletti, P | 1 |
| Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L | 1 |
| Kollar, LE; Lawrence, TS; Maybaum, J; Morgan, MA; Normolle, DP; Parsels, LA | 1 |
| Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M | 1 |
| Bafaloukos, D; Bobos, M; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalogera-Fountzila, A; Kalogeras, KT; Karayannopoulou, G; Kosmidis, P; Koutras, AK; Linardou, H; Murray, S; Samantas, E; Xiros, N | 1 |
| Boehm, KA; Cartwright, T; Richards, DA | 1 |
| Harris, P; Hartwell, D; Loveman, E; Takeda, A; Welch, K | 1 |
| Cohen, MH; Ibrahim, A; Johnson, J; Justice, R; Ko, CW; Pazdur, R; Ryan, Q; Sridhara, R | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P | 1 |
| Dobrova, NV; Lichinitser, MR; Semenov, NN; Vakhabova, JV | 1 |
| Höhler, T; Oettle, H; Staib, L | 1 |
| Heinemann, V | 1 |
| Baron, A; Basche, M; Dancey, J; Eckhardt, SG; Gore, L; Gustafson, DL; Holden, SN; Lam, ET; O'Bryant, CL; Serkova, N | 1 |
| Chen, E; Feld, R; Gauthier, I; Goss, G; Laurie, S; Leighl, N; Powers, J; Seymour, L; Shepherd, FA | 1 |
| Hay, JW; Le, QA | 1 |
| Davies, JM; Goldberg, RM | 1 |
| Amonkar, MM; Cameron, D; Cella, D; Geyer, CE; Segreti, A; Stein, S; Walker, M; Zhou, X | 1 |
| Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C | 1 |
| Anraku, M; Bezjak, A; Burkes, R; Cho, BC; de Perrot, M; Feld, R; Johnston, MR; Keshavjee, S; Leighl, N; Roberts, H; Tsao, MS | 1 |
| Blum, JL; Brufsky, A; Christodoulou, C; Ciruelos, E; Dharan, B; Diéras, V; Gori, S; Greil, R; Lin, NU; Liu, MC; Loibl, S; Lossignol, D; Oliva, C; Paoletti, P; Paul, D; Roché, H; Roychowdhury, D; Rubin, SD; Stemmler, HJ; Steplewski, K; Wardley, A; Winer, EP; Yardley, D; Zembryki, D | 1 |
| Brell, JM; Dranko, S; Evans, T; Kiefer, GJ; Lenzner, D; Matin, K; Ramanathan, RK; Rath, L; Schlesselman, JJ; Schmotzer, A; Volkin, RL | 1 |
| Burstein, HJ; Gelman, RS; Harris, LN; Mayer, EL; Partridge, AH; Schumer, ST; Winer, EP | 1 |
| Bennouna, J; Cosaert, J; Gill, S; Humblet, Y; Moore, MJ; Scheithauer, W; Shang, A; Van Cutsem, E; Van Laethem, JL; Verslype, C; Vervenne, WL | 1 |
| Altman, RB; Brunak, S; Hansen, NT | 1 |
| Finn, RS; Zhu, AX | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Elzawawy, A | 1 |
| Batra, SK; Davis, JS; Davis, TL; Hauke, R; Lin, FF; Lin, MF; Schutte, R; Zelivianski, S; Zhang, L | 1 |
| Choo, SP; Leong, SS; Li, HH; Lim, WT; Tan, EH; Tan, SH; Tham, CK; Toh, CK | 1 |
| Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Sargent, M; Schafer, C; Seufferlein, T | 1 |
| Li, J; Saif, MW | 1 |
| Cathomas, R; von Moos, R | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Boyer, MJ; Chen, YM; Chua-Tan, M; Chui, W; Ignacio, J; Jin, K; Johnston, M; Lee, JS; Liao, M; Mok, TS; Srimuninnimit, V; Sriuranpong, V; Sudoyo, AW; Wu, YL; Yu, CJ; Zhang, L; Zhou, C | 1 |
| Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, T; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Märten, A; Neugebauer, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C | 1 |
| Frampton, JE | 1 |
| Teng, KY; Xu, RH | 1 |
| Capri, G; Chang, J; Chen, SC; Conte, P; Cwiertka, K; De Placido, S; Jerusalem, G; Jiang, Z; Johnston, S; Kaufman, B; Link, J; Oliva, C; Parikh, R; Preston, A; Ro, J; Rosenlund, J; Schütte, J; Selzer, M; Zembryki, D | 1 |
| Clegg, A; Jones, J; Picot, J; Takeda, A; von Keyserlingk, C | 1 |
| Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Thomas, K; Watkins, D; Webb, J | 1 |
| Berton-Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Sadot-Lebouvier, S; Zanetti, A | 1 |
| Guarneri, V | 1 |
| Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
| Schwartz, J | 1 |
| Cancello, G; Colleoni, M; Montagna, E; Rizzo, S; Scarano, E; Torrisi, R | 1 |
| Ardavanis, A; Doufexis, D; Karagiannis, A; Kountourakis, P; Rigatos, G; Tzovaras, AA | 1 |
| Pikó, B | 1 |
| Lai, JI; Lin, PC; Tzeng, CH; Wang, WS | 1 |
| Abbruzzese, JL; El-Rayes, BF; Ferris, AM; Hess, K; Javle, MM; Kaseb, AO; Philip, PA; Sarkar, FH; Shields, AF; Varadhachary, GR; Wolff, RA | 1 |
| Bergsland, EK; Dito, E; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Schillinger, B; Scott, J; Tempero, MA; Venook, AP | 1 |
| Ferraz, MB; Puga, ME; Riera, R; Soárez, PC | 1 |
| Ashley, S; Bhatti, R; Camburn, T; Chan, S; Davidson, N; Johnston, SR; Miles, D; Nouras, H; Shehata, M; Sutherland, S; Wardley, A | 1 |
| Glynne-Jones, R; Harrison, M; Mawdsley, S | 1 |
| Jørgensen, JT | 1 |
| Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH; Schaffert, JM | 1 |
| Frieling, T; Graeven, U; Hegewisch-Becker, S; Lehnert, L; Reinacher-Schick, A; Schmiegel, W; Trarbach, T; Vanhoefer, U | 1 |
| Garber, K | 1 |
| Deng, X; Dewan, MZ; Kuroi, K; Saji, S; Takada, M; Terunuma, H; Toi, M; Yamamoto, N | 1 |
| Mehta, SP | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Glimelius, B | 1 |
| Barlési, F; Baudrin, L; Bréchot, JM; Debieuvre, D; Gounant, V; Lebeau, B; Milleron, B; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Angelini, PD; Arribas, J; Aura, C; Baselga, J; Cameron, D; Chandarlapaty, S; Ellis, C; Gagnon, R; Geyer, C; Gomez, H; Guzman, M; Jimenez, J; Koehler, M; Parra, JL; Prudkin, L; Rosen, N; Sánchez, G; Scaltriti, M | 1 |
| Fietkau, R; Heinemann, V; Knoefel, WT; Oettle, H; Tannapfel, A | 1 |
| Chefrour, M; Ciccolini, J; Ferri-Dessens, RM; Fischel, JL; Formento, P; Francoual, M; Giacometti, S; Marouani, H; Mercier, C; Milano, G; Renée, N | 1 |
| Bou Reslan, H; Cao, TC; Carano, RA; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, WF; Fuh, G; Hamilton, P; Ho, CC; Johnson, L; Koeppen, H; Lee, CV; Lima, A; Molina, R; Nannini, MA; Plowman, GD; Singh, M; Thompson, JD; Yu, RX | 1 |
| Bilici, A; Gumus, M; Kefeli, AU; Kefeli, U; Seker, M; Ustaalioglu, BB; Yildirim, ME | 1 |
| Cristofanilli, M | 1 |
| Pownall, M | 1 |
| Blackhall, FH; Kennedy, SJ; Milenkova, T; Nicolson, M; O'brien, M; Schmid, P; Taylor, P; Thatcher, N | 1 |
| Kaley, K; Penney, R; Saif, MW; Syrigos, K | 1 |
| Cognetti, F; Crinò, L; Fabi, A; Foglietta, J; Giannarelli, D; Gori, S; Metro, G; Mottolese, M; Papaldo, P; Russillo, M; Stocchi, L; Vidiri, A | 1 |
| Cameron, D; Casey, M; Geyer, CE; Imwalle, B; Newstat, B; Oliva, C | 1 |
| Chin, K; da Cunha Santos, G; Dhani, N; Kamel-Reid, S; Ludkovski, O; Moore, MJ; Parulekar, W; Squire, J; Tsao, MS; Tu, D | 1 |
| Chiu, YF; Kuo, YH; Lin, YW; Su, YC; Tsai, MS | 1 |
| Fusi, A; Keilholz, U; Liu, Z; Schmittel, A; Schneider, A; Tinhofer, I | 1 |
| Bai, CM; Cheng, YJ; Zhang, ZJ | 1 |
| Baas, J; Bloemendal, HJ; Boven, E; de Graaf, H; Hop, WC; Kroep, JR; Linn, SC; Mandjes, IA; Nortier, JW; Schröder, CP; Smit, WM; van den Bosch, J; Vermeulen, GJ | 1 |
| Egerton, N | 1 |
| Der, CJ; Roberts, PJ; Socinski, MA; Stinchcombe, TE | 1 |
| Barriuso, J; Belda-Iniesta, C; Borrega, P; Castro, J; Feliu, J; González-Barón, M; León, A; López, M; López-Gómez, L; Martínez, V | 1 |
| Bang, YJ; Cha, Y; Ham, HS; Han, SW; Im, SA; Im, YH; Kim, HP; Kim, TY; Lee, KS; Oh, DY; Park, IH; Park, JW; Rhee, J; Ro, J | 1 |
| Clynes, M; McDermott, R; O'Connor, R; Sheikh, R; Walsh, N | 1 |
| Frank, RC; Lincer, R; Mody, K; Strauss, E | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Liu, F; Liu, H; Ning, K; Wang, F; Wang, Y; Yu, J; Yuan, S; Zhang, J | 1 |
| Aono, T; Iwase, K; Nakamura, Y; Nomura, M; Tanaka, Y | 1 |
| Bahary, N; Bao, PQ; Bartlett, DL; Hughes, SJ; Krasinkas, A; Lee, KK; Lembersky, BC; Moser, AJ; Ramanathan, RK; Zeh, HJ | 1 |
| Guan, ZZ; Guo, GF; Wan, DS; Wu, PH; Xia, JC; Xia, LP; Zeng, YX; Zhang, B | 1 |
| Dobbins, TA; Drew, AK; Harris, CA; Pearson, S; Ward, RL | 1 |
| Holzman, DC | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Daum, S; Epple, HJ; Grozdanovic, Z; Kunkel, J; Loddenkemper, C; Schmittel, A; Schulze, K; Zeitz, M | 1 |
| Choi, YJ; Chung, JH; Kim, CH; Kim, HR; Lee, CT; Lee, JC; Lee, JS; Rho, JK; Xu, X; Yoon, HI | 1 |
| Chen, E; Gauthier, I; Gill, S; Goel, R; Hedley, D; Jonker, D; McIntosh, L; Moore, MJ; Renouf, DJ; Seymour, L; Southwood, B; Walde, D; Walsh, W | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Iguchi, H; Ioka, T; Ito, T; Komatsu, Y; Nakachi, K; Nakagawa, K; Nakamori, S; Ohkawa, S; Okusaka, T; Yamao, K | 1 |
| Chen, B; Liu, S; Wang, D; Wang, Y; Wu, J; Zhao, W | 1 |
| Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G | 1 |
| Beham, A; Bodo, K; Lackner, K; Liegl, B; Martin, D; Tsybrovskyy, O | 1 |
| Bar-Sela, G; Haim, N; Nasrallah, H | 1 |
| Fridlyand, J; Fyfe, G; Kaiser, LD | 1 |
| Merchant, NB; Nagaraj, NS; Washington, MK | 1 |
| Egloff, AM; Grandis, JR | 1 |
| Galettis, P; Links, M; Luk, PP | 1 |
| Azzariti, A; Bocci, G; Chiarappa, P; Del Bufalo, D; Del Tacca, M; Fioravanti, A; Mangia, A; Paradiso, A; Porcelli, L; Quatrale, AE; Sebastian, S; Simone, GM; Sini, P | 1 |
| Bharadwaj, RR; Chen, EX; Jarvi, A; Kamel-Reid, S; Le Tourneau, C; Mann, V; Perez-Ordonez, B; Siu, LL; Wang, L; You, B | 1 |
| Oberstein, PE; Saif, MW | 1 |
| Gu, FY; Hu, XY; Li, MD; Shen, H; Yuan, Y; Zhong, X | 1 |
| Cabebe, EC; Fisher, GA; Sikic, BI | 1 |
| Bang, YJ; Kang, HJ; Kim, BS; Kim, JS; Lee, KH; Lee, KW; Oh, DY; Park, YS; Ryoo, HM; Sohn, CH; Song, HS; Zang, DY | 1 |
| Collisson, EA; Cooc, J; Danenberg, KL; Feiler, HS; Gibb, WJ; Gray, JW; Gu, S; Hanahan, D; Jakkula, L; Kim, GE; Ko, AH; Olshen, AB; Olson, P; Sadanandam, A; Spellman, PT; Tempero, MA; Truitt, M; Weinkle, J | 1 |
| Agrogiannis, G; Gamaletsou, MN; Kechagias, G; Papageorgiou, A; Syrios, J; Tsavaris, N; Xynos, ID | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| Chi, HD; Chua, D; Jiang, ZF; Liu, DG; Luo, RC; Martin, AM; Newstat, B; Preston, A; Shao, ZM; Wang, L; Wang, XJ; Xu, BH; Yeo, W; Yu, SY | 1 |
| Balaraman, S; Ballouz, S; Boxwala, IG; Cotant, MB; Hardy-Carlson, M; Jaiyesimi, IA; Jury, RP; Margolis, J; Marvin, KS; Nadeau, L; Robertson, JM; Wallace, M; Ye, H | 1 |
| Borštnar, S; Cwiertka, K; Das Gupta, A; Greil, R; Koza, I; Linn, M; Marcou, Y; Petráková, K; Pikiel, J; Steger, GG; Wojtukiewicz, MZ | 1 |
| Alberti, D; Bowen, CJ; Dar, MM; Dennie, TW; Fleming, RA; Holen, KD; Loconte, N; Mulkerin, D; Oliver, K | 1 |
| Gunn, JR; Korc, M; Sempere, LF | 1 |
| Balaraman, S; Gustafson, G; Huang, J; Jury, R; Khilanani, P; Margolis, J; McIntosh, B; Nadeau, L; Robertson, JM | 1 |
| Chefrour, M; Ciccolini, J; Denden, A; Fischel, JL; Formento, P; Giacometti, S; Iliadis, A; Milano, G; Renée, N | 1 |
| Guo, H; Hu, X; Jia, Z; Shao, Z; Sun, S; Wang, B; Wang, L; Wang, Z; Zhang, J; Zhang, Q | 1 |
| Amonkar, MM; Browning, D; Cameron, D; Delea, TE; Karnon, J; Sofrygin, O; Tappenden, P; Walker, MD | 1 |
| Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D | 1 |
| Bakri, K; Beaumont, JL; Bradford, DS; Crane, JM; Harper, HD; Hensing, TA; Lee, CB; McElroy, E; Moore, DT; Niell, HB; Pal, S; Peterman, AH; Schwartz, G; Socinski, MA; Stinchcombe, TE; Taylor, M | 1 |
| Beijnen, JH; Benhadji, KA; Callies, S; Garcia-Ribas, I; Jansen, RS; Koolen, SL; Kronemeijer, RH; Langenberg, MH; Nol, A; Schellens, JH; Slapak, CA; Voest, EE; Witteveen, PO | 1 |
| Chen, G; Chen, L; Feng, J; Hu, C; Huang, J; Liu, XQ; Lu, S; Luo, Y; Ma, J; Ren, S; Wang, C; Wang, J; Wu, YL; Xiu, Q; Ye, M; You, C; Zhang, L; Zhang, S; Zhang, Y; Zhi, X; Zhou, C; Zhou, S | 1 |
| Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S | 1 |
| Dennie, T; Holen, KD; Mohammed, TA | 1 |
| Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y | 1 |
| Baek, KK; Choi, YL; Jang, HL; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lim, DH; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS; Yi, JH | 1 |
| Chen, C; D'Andrea, G; Drullinsky, P; Feigin, K; Gajria, D; Gonzalez, J; Hudis, CA; Lake, D; Norton, L; Patil, S; Theodoulou, M; Traina, TA | 1 |
| Ait-Tihyaty, M; Jean-Claude, BJ; Mihalcioiu, C; Rachid, Z | 1 |
| Cerny, T; De Dosso, S; Koeberle, D; Renggli, V; Saletti, P; Sessa, C | 1 |
| Barlesi, F; Bota, S; Chouaid, C; Corre, R; Delhoume, JY; Dujon, C; Falchero, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Benhaim, L; Bohanes, PO; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; Labonte, MJ; Ladner, RD; Lenz, HJ; Ning, Y; Wilson, PM; Yang, D; Zhang, W | 1 |
| Jung, SY; Kang, HS; Kim, SW; Ko, K; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J; Shin, KH | 1 |
| Huang, J; Margolis, J; Nadeau, L; Robertson, JM; Yan, D; Ye, H | 1 |
| Asmis, TR; Hilton, JF; Jonker, DJ; Moore, MJ; O'Callaghan, CJ; Parulekar, W; Powell, ED; Tu, D; Vickers, MM | 1 |
| Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH | 1 |
| Conroy, T; Mitry, E | 1 |
| Aranda, E; Arrivi, A; Díaz-Rubio, E; Galán, M; Irigoyen, A; Manzano, JL; Mendez, MJ; Pericay, C; Rivera, F; Safont, MJ; Sastre, J; Valladares-Ayerbes, M | 1 |
| Bollag, G; Bradley, WD; Heimbrook, D; Higgins, B; Kolinsky, K; Kopetz, S; Lee, RJ; Lestini, B; Packman, K; Schostack, K; Simcox, ME; Su, F; Yang, H | 1 |
| Jensen, LH | 1 |
| Chang, HM; Chang, JS; Choi, HJ; Jang, JS; Jeung, HC; Kang, HJ; Kang, JH; Kang, WK; Kim, JS; Lee, HW; Lee, J; Lee, MA; Lim, HY; Park, JO; Park, SH; Park, YS; Shin, DB; Sun, JM | 1 |
| Ishiba, T; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Sugimoto, H | 1 |
| Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M | 1 |
| Chen, H; Guo, HC; Lin, SZ; Liu, DL; Liu, HB; Ni, ZL; Tong, HF; Wang, ZH; Wei, WT | 1 |
| Bazzan, AJ; Deshmukh, S; Levine, M; Littman, S; Mitchell, E; Monti, DA; Newberg, AB; Pillai, MV; Yeo, CJ; Zabrecky, G | 1 |
| Altavilla, G; Artal, A; Baize, N; Bearz, A; Bernabe, R; Bombaron, P; Bover, I; Carcereny, E; Cobo, M; Corre, R; Cortesi, E; Dansin, E; de Aguirre, I; de Castro, J; De Marinis, F; Domine, M; Drozdowskyj, A; Felip, E; Ferrera-Delgado, L; Garcia-Campelo, R; Garcia-Gomez, R; Garrido, P; Gebbia, V; Gervais, R; Illiano, A; Insa, A; Isla, D; Jimenez, U; Longo, F; Lopez-Vivanco, G; Massuti, B; Mazieres, J; Milella, M; Molina, MA; Molinier, O; Moran, T; Moreno, MA; Muñoz-Langa, J; Pallares, C; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Ramirez, JL; Reguart, N; Robinet, G; Rodriguez-Abreu, D; Rolfo, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Terrasa, J; Valdivia, J; Vergnenegre, A | 1 |
| Cha, YJ; Go, S; Hwang, IG; Jang, JS; Kang, JH; Kang, MH; Kwon, HC; Lee, GW; Lee, S; Oh, SY | 1 |
| Ahn, JS; Ahn, MJ; Han, JH; Han, JY; Jo, SJ; Kim, HT; Kim, HY; Kim, SW; Lee, DH; Lee, JS; Lee, JW; Park, K; Suh, C; Yoon, SJ; Yun, T | 1 |
| Liu, BX; Ying, JE; Zhu, LM | 1 |
| Berard, H; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Falchero, L; Greillier, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Saif, MW; Strimpakos, AS; Syrigos, KN | 1 |
| Aiba, S; Fujimura, T; Haga, T; Hashimoto, A; Hidaka, T; Mizuashi, M; Onami, K; Watabe, A | 1 |
| Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M | 1 |
| Bagnardi, V; Bertolini, F; Calleri, A; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Intra, M; Luini, A; Montagna, E; Pastrello, D; Perri, G; Rampinelli, C; Veronesi, P; Viale, G | 1 |
| Aklilu, M; Bernard, SA; Blackstock, AW; Davies, JM; Goldberg, RM; Ivanova, A; O'Neil, BH; Raftery, L; Tepper, JE | 1 |
| Bahlo, M; Klapdor, R; Klapdor, S | 1 |
| Guo, Z; Li, J | 1 |
| Hong, TH; Jeon, EK; Ko, YH; Lee, IS; Lee, MA; Won, HS; You, YK | 1 |
| Amler, L; Girish, S; Guardino, E; Krop, IE; LoRusso, P; Lu, M; Miller, KD; Modi, S; Rodriguez, G; Rugo, HS; Winer, EP; Yardley, D; Zheng, M | 1 |
| Houts, AC; Leon, L; Miller, PJ; Reyes, C; Satram-Hoang, S; Schwartzberg, LS; Stepanski, EJ; Walker, MS; Wojtowicz-Praga, S | 1 |
| Clarke, S; Clingan, P; De Boer, R; Johnston, M; Michael, M; Pavlakis, N | 1 |
| Baudrin, L; Cadranel, J; Coëtmeur, D; Duruisseaux, M; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Westeel, V; Wislez, M | 1 |
| Han, JY; Kim, HT; Kim, SH; Lee, JS; Lee, Y; Yun, T | 1 |
| Baake, G; Boeck, S; Clemens, MR; Gauler, TC; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Höhler, T; Jung, A; Kettner, E; Klein, S; Ko, YD; Kojouharoff, G; Märten, A; Neugebauer, S; Rubanov, O; Vehling-Kaiser, U; von Weikersthal, LF; Waldschmidt, D; Winkelmann, C | 1 |
| Alam, Y; Butts, C; Cantile, F; Ciardiello, F; Cinieri, S; da Cunha Santos, G; Di Maio, M; Favaretto, A; Feld, R; Felletti, R; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, N; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, A; Saieg, M; Siena, S; Tortora, G; Tsao, MS; Wierzbicki, R | 1 |
| Kato, Y; Kawamura, H; Makino, T; Nishina, M; Yokoyama, E | 1 |
| Ramfidis, VS; Saif, MW; Strimpakos, AS; Syrigos, KN | 1 |
| Auliac, JB; Chouaid, C; Dujon, C; Le Caer, H; Locher, C; Monnet, I; Thomas, P; Vergnenegre, A | 1 |
| Chung, JS; Im, YH; Kim, S; Kim, TY; Moon, H; Park, S; Rha, SY; Ro, J; Santillana, S | 1 |
| Bang, YJ; Bates, M; Cha, Y; Haddad, M; Han, SW; Huang, W; Im, SA; Kim, TY; Lee, KS; Lie, Y; Oh, DY; Paquet, A; Park, IH; Ro, J; Sherwood, T; Weidler, J | 1 |
| O'Reilly, EM | 1 |
| Lim, E; Lin, NU | 1 |
| Choi, M; Kim, R; Razzaque, S | 1 |
| Kimura, Y; Morikawa, N; Murakami, K; Nagano, Y; Tabata, T; Yanagisawa, S | 1 |
| Barlési, F; Chouaid, C; Crequit, J; Devouassoux-Shisheboran, M; Falchero, L; Fournel, P; Gervais, R; Le Caer, H; Léna, H; Milleron, B; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Ségura-Ferlay, C; Taron, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B | 1 |
| Benjamin, L; Buthion, V; Farah, B; Iskedjian, M; Rioufol, C; Vidal-Trécan, G | 1 |
| Drebin, JA; Pippin, JA; Singla, S | 1 |
| Baselga, J; Blackwell, K; Diéras, V; Fang, L; Gianni, L; Guardino, E; Krop, IE; Lu, MW; Miles, D; Oh, DY; Olsen, S; Pegram, M; Verma, S; Welslau, M | 1 |
| Biesma, B; Heideman, D; Smit, EF; Thunnissen, E; van Riel, S | 1 |
| Bahleda, R; Blay, JY; Dieras, V; LoRusso, P; Macaulay, VM; Mery-Mignard, D; Middleton, MR; Protheroe, AS; Sessa, C; Soria, JC; Tolcher, A | 1 |
| Barrick, B; Fraga, G; Matthys, B | 1 |
| Bartsch, R; Preusser, M | 1 |
| Bachelot, T; Campone, M; Cropet, C; Curé, H; Dalenc, F; Diéras, V; Domont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Jimenez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Pierga, JY; Romieu, G | 1 |
| Belliere, A; Chevrier, R; Chollet, P; Dillies, AF; Durando, X; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Thivat, E; Van Praagh, I | 1 |
| Chiba, A; Inaba, M; Inari, H; Ino, H; Kojima, I; Kuroda, K; Matsuo, A; Matsuura, H; Mukaibashi, T; Shimizu, S; Suganuma, N; Yamanaka, T; Yoshida, A | 1 |
| Fujita, Y; Goto, M; Hamaoka, A; Imai, A; Mizuta, N; Morita, M; Nakatsukasa, K; Sakaguchi, K; Shouji, M; Taguchi, T; Umeda, Y | 1 |
| Alam, Y; Bianco, R; Butts, C; Ciardiello, F; Cinieri, S; Di Maio, M; Fasano, M; Favaretto, A; Feld, R; Felletti, R; Fregoni, V; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, NB; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Ravaioli, A; Riccardi, F; Rossi, A; Siena, S; Signoriello, S; Spatafora, M; Tsao, MS; Wierzbicki, R | 1 |
| Kay, M | 1 |
| Barner, M; Boeck, S; Clemens, MR; Egg, R; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Goritschan, C; Greten, TF; Heinemann, V; Jung, A; Kirchner, T; Klein, S; Kojouharoff, G; Laubender, RP; Mansmann, U; Märten, A; Neumann, J; Vehling-Kaiser, U; Winkelmann, C | 1 |
| Boursier, C; Bylicki, O; Dot, JM; Peloni, JM | 1 |
| Krug, S; Michl, P | 1 |
| Benekli, M; Berk, V; Boruban, C; Buyukberber, S; Cetin, B; Coskun, U; Dane, F; Harputluoglu, H; Isıkdogan, A; Kaplan, MA; Koca, D; Koral, L; Oksuzoglu, B; Sevinc, A; Turker, I; Ulas, A; Uncu, D; Yilmaz, B | 1 |
| Andreu, X; Baena, C; Bronchud, MH; Castillo, S; Escriva de Romaní, S; Esquius, J; Fernández, A; Julia, JC; Mourelo, S; Murillo, J; Romero, R | 1 |
| Horiguchi, N; Kakizaki, S; Mori, M; Nakajima, Y; Sato, K; Sunaga, N; Takagi, H | 1 |
| Adjei, AA; Ansari, RH; Dy, GK; Lyss, AP; Mandrekar, SJ; Meyers, JP; Molina, JR; Nelson, GD; Ross, HJ; Schild, SE; Stella, PJ | 1 |
| Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H | 1 |
| Nieder, C | 1 |
| Basavalingaiah, A; Madhusudhan, N; Revannasiddaiah, S; Susheela, SP | 1 |
| Bachelot, T; Campone, M; Cropet, C; Diéras, V; Jimenez, M | 1 |
| Bachelot, T; Bonneterre, J; Gilabert, M; Gonçalves, A; Heudel, P; Labidi-Gally, I; Le Rhun, E; Pierga, JY | 1 |
| Akman, T; Alici, S; Arslan, UY; Boruban, C; Coskun, U; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Inanc, M; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Oksuzoglu, B; Ozdemir, NY; Sener, N; Suner, A; Tarhan, MO; Urakci, Z; Yildiz, R | 1 |
| Cai, H; Canto, MI; Chang, KJ; Donehower, RC; Herman, JM; Hoffe, SE; Klapman, J; Laheru, DA; Pawlik, TM; Reid, T; Rosemurgy, A; Savage, DT; Shah, RJ; Taylor, GE; Tran, PT; Wang, H; Wild, AT; Wolfgang, CL; Ziegler, MA | 1 |
| Cheng, X; Li, H; Li, L; Li, M; Lu, W; Wang, X; Zhou, T | 1 |
| Grigorieva, J; Lee, CB; Moore, DT; Peterman, AH; Roder, J; Socinski, MA; Stinchcombe, TE | 1 |
| Asaoka, Y; Ijichi, H; Ikenoue, T; Isayama, H; Koike, K; Miyabayashi, K; Mohri, D; Morishita, Y; Moses, HL; Nakai, Y; Omata, M; Tada, M; Tateishi, K; Yamamoto, K | 1 |
| Goyal, A; Singh, N | 1 |
| Aldana, GQ; DE LA Cámara Gómez, J; Fernández, MJ; Fernández, MS; Folgar, SC; López, MR; López, R; Méndez, CM; Reinoso, CR; Vázquez, MR | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, HJ; Kim, HP; Kim, MS; Kim, TY; Lee, GS; Oh, DY; Yoon, YK | 1 |
| Chen, JZ; Di, MY; Ding, H; Huang, YF; Mao, C; Tang, JL; Wu, XY; Yang, ZY; Yuan, JQ; Zheng, DY | 1 |
| Kim, R; Kothari, N; Saif, MW | 1 |
| Dirix, LY; Dirix, M; Huget, P; Rutten, A | 1 |
| Li, J; Lu, Q; Ouyang, L; Peng, L; Tan, C; Wang, S; Zeng, X | 1 |
| Chan, KS; Lim, KH; Lim, WT; Lynette, O; Montoya, J; Ng, QS; Sakktee Krisna, S; Takano, A; Tan, DS; Tan, EH | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Cassidy, J; Hochster, H | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Bhuva, N; Buckley, A; Harrison, M; Kelly, C; Saunders, M | 1 |
| Barlési, F; Bylicki, O; Chouaid, C; Corre, R; Créquit, J; Dubos, C; Falchero, L; Ferlay, C; Fournel, P; Lavolé, A; Le Caer, H; Linard, P; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Au, JS; Brown, C; Chu, da T; Gebski, V; Gralla, RJ; Hirsh, V; Ho, JC; Inoue, A; Lee, CK; Lee, SM; Osorio Sanchez, JA; Tan, EH; Thongprasert, S; Tsai, CM; Vu, VV; Yang, JC; Zaatar, A | 1 |
| Chouaid, C; Pérol, D; Pérol, M | 1 |
| Bai, H; Chen, J; Fang, F; Fang, J; Feng, Q; Feng, Y; Li, S; Lv, C; Ma, Y; Pei, Y; Wang, J; Wang, Y; Wu, N; Yan, S; Yang, Y; Zhao, B; Zheng, Q | 1 |
| Abbruzzese, JL; Carlson, P; Fogelman, DR; George, B; Javle, M; Khalil, MA; Overman, M; Qiao, W; Varadhachary, G; Wolff, RA | 1 |
| Duffy, A; Greten, TF; Liewehr, DJ; Rahma, OE; Steinberg, SM | 1 |
| Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Belbaraka, R; Elomrani, A; Ismaili, N; Khouchani, M; Tahri, A | 1 |
| Bian, L; Jiang, Z; Wang, T; Zhang, S | 1 |
| Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L | 1 |
| Bara, I; Chang, GC; Chen, YM; Cheng, A; Fuerte, F; Ho, J; Jin, K; Kurnianda, J; Ladrera, G; Lee, JS; Lee, V; Liao, M; Liu, HE; Margono, B; Mok, T; Pan, H; Qian, X; Sandoval-Tan, J; Seetalarom, K; Srimuninnimit, V; Sriuranpong, V; Sun, Y; Syahruddin, E; Thongprasert, S; Truman, M; Wang, J; Wu, YL; Yu, CJ; Zhang, L; Zhou, C; Zhu, Y | 1 |
| Ariad, S; Geffen, DB; Geva, S; Lazarev, I | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, Y; Yun, T | 1 |
| Huber, KE; Saif, MW; Savir, G | 1 |
| Ohkawa, S; Sakamoto, Y; Ueno, M | 1 |
| Ezaki, T; Iguchi, T; Ito, S; Koga, T; Nozoe, E; Nozoe, T; Ohga, T | 1 |
| Bria, E; Cognetti, F; Gamucci, T; Gelibter, A; Mansueto, G; Milella, M; Moscetti, L; Ruggeri, EM; Sperduti, I; Vaccaro, V | 1 |
| Gorbunova, VA; Moskvina, EA; Naskhletashvili, DR | 1 |
| Andersen, RF; Christensen, Rd; Hansen, TF; Jakobsen, A; Johnsson, A; Sørensen, FB | 1 |
| Amano, R; Hirakawa, K; Hirata, K; Kimura, K; Komoto, M; Murata, A; Nakata, B | 1 |
| Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K | 1 |
| Ait-Tihyaty, M; Jean-Claude, BJ; Larroque-Lombard, AL; Rachid, Z | 1 |
| Stinchcombe, TE | 1 |
| Bachelot, T; Bidard, FC; Campone, M; Cropet, C; Curé, H; Dalenc, F; Dômont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Mahier Aït-Oukhatar, C; Pierga, JY; Romieu, G; Tresca, P | 1 |
| Cao, L; Freeman, JW; Hill, P; Nawrocki, ST; Peterson, L; Venkatasubbarao, K; Zhao, S; Zhou, Q | 1 |
| Aiba, K; Fujiwara, Y; Furukawa, K; Futagawa, Y; Kitamura, H; Misawa, T; Shiba, H; Tsutsui, N; Uwagawa, T; Yanaga, K | 1 |
| Benekli, M; Berk, V; Boruban, C; Buyukberber, S; Cetin, B; Coskun, U; Dane, F; Harputluoglu, H; Kaplan, MA; Koca, D; Koral, L; Oksuzoglu, B; Sevinc, A; Turker, I; Ulas, A; Uncu, D; Yilmaz, B | 1 |
| Ahuja, A; Chan, AT; Chan, C; Chan, SL; Dattatray, RD; Ho, WM; Hui, EP; King, AD; Lau, W; Ma, BB; Mo, F; Poon, A; To, KF; Wong, SC | 1 |
| Barry, ST; Hoff, PM; Jürgensmeier, JM; Morgan, SR; Pommier, AJ; Robertson, JD; Spencer, SK | 1 |
| Akça, Z; Büyükçelik, A; Erden, A; Mutlu, H | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Ryan, AJ; Sawyer, MB; Scriver, T | 1 |
| Chishima, T; Endo, I; Ichikawa, Y; Ishikawa, T; Kita, K; Narui, K; Sasaki, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yoneyama, S | 1 |
| Althaus, B; Diéras, V; Fang, L; Guardino, E; Hurvitz, SA; Lalla, D; Miles, D; Sohn, JH; Welslau, M | 1 |
| Gamucci, T; Mauri, M; Mentuccia, L; Moscetti, L; Pavese, I; Pizzuti, L; Sperduti, I; Vaccaro, A; Vici, P; Zampa, G | 1 |
| Ferry, D; Fournier, M; Gebski, V; Gordon, S; Karapetis, CS; Price, TJ; Ransom, D; Simes, RJ; Tebbutt, N; Wilson, K; Yip, D | 1 |
| Furuse, J | 1 |
| Chang, GJ; Clemons, MV; Crane, CH; Das, P; Delclos, ME; Eng, C; Garrett, CR; Kopetz, SE; Krishnan, S; Maru, DM; Munsell, MF; Rodriguez-Bigas, MA; Shureiqi, I; Skibber, JM; You, YN | 1 |
| Antoine, M; Bonnette, P; Cadranel, J; Cazes, A; Duruisseaux, M; Girard, N; Mazieres, J; Monnet, I; Ung, M; Vieira, T; Wislez, M | 1 |
| Egawa, C; Kagawa, Y; Kato, T; Katsura, Y; Nakahira, S; Okishiro, M; Sakisaka, H; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H | 1 |
| Brain, E; Briggs, K; Caglevic, C; Desilvio, M; Janni, W; Karaszewska, B; Marini, L; Papadimitriou, C; Pikiel, J; Potemski, P; Salat, C; Sarosiek, T; Staroslawska, E | 1 |
| Alcolea, V; Aparicio, J; Corbellas, M; Diaz Beveridge, R; Fonfría, M; García, J; Giménez, A; Montalar, J; Segura, Á | 1 |
| Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Kim, M; Lee, KY; Li, W; Lu, S; Massey, D; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C | 1 |
| Chan, EH; Chan, SL; Chan, ST; He, ZX | 1 |
| Amiri Kordestani, L; Blumenthal, G; Booth, B; Cortazar, P; Ibrahim, A; Justice, R; Liu, Q; Mehrotra, N; Rahman, A; Schrieber, S; Song, P; Tang, S; Wang, J; Wang, Y; Xu, Q | 1 |
| Chiba, T; Kanai, M; Kawaguchi, Y; Kodama, Y; Matsumoto, S; Mori, Y; Nishimura, T; Takaori, K; Uemoto, S; Uza, N; Xue, P | 1 |
| Şendur, MA; Uncu, D; Zengin, N | 1 |
| Barbachano, Y; Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Watkins, DJ; Webb, J | 1 |
| Altimari, A; Di Tullio, P; Fiorentino, M; Giunchi, F; Gruppioni, E; Martorana, G; Pinto, C | 1 |
| Barni, S; Brandes, AA; Caffo, O; Cerea, G; Ciardiello, F; Crinò, L; Cruciani, G; De Marinis, F; Fasola, G; Favaretto, AG; Ferrari, S; Ferraù, F; Galetta, D; Genestreti, G; Gridelli, C; Grossi, F; Iannacone, C; Luciani, A; Novello, S; Zilembo, N | 1 |
| Cao, KI; Kirova, YM | 1 |
| Hayashi, M; Hironaka, H; Morita, N; Orita, M | 1 |
| Anderson, E; Bahary, N; Charpentier, K; Clark, A; Kennedy, T; Lopez, CD; McNulty, B; Miner, T; Safran, H; Schumacher, A; Shipley, J; Sio, T; Sun, W; Vakharia, J; Whiting, S | 1 |
| Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G | 1 |
| Bartosiewicz, M; Boeck, S; Haas, M; Heinemann, V; Isaacson, J; Kirchner, T; Kleespies, A; Kruger, S; Laubender, RP; Mann, E; Ormanns, S; Raponi, M | 1 |
| Au, HJ; Chen, E; Dhani, N; Gill, S; Hedley, D; Kamel-Reid, S; Moore, MJ; Renouf, DJ; Tang, PA; Tran-Thanh, D; Tsao, MS; Wang, L | 1 |
| Belani, CP; Gusani, N; Jiang, Y; Kaifi, J; Kimchi, ET; Mackley, HB; Staveley-O'Carroll, KF; Zhu, J | 1 |
| Choi, DW; Choi, JY; Choi, MK; Choi, SH; Heo, JS; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, HY; Park, JO; Park, YS | 1 |
| Conte, M; Ellingrod, VL; King, AN; O'Malley, M; Ramnath, N | 1 |
| Christopoulou, A; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Katopodis, O; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Polyzos, A; Souglakos, J; Stathopoulos, E | 1 |
| Alejandre, MJ; Aránega, A; Caba, O; Delgado, JR; Iglesias, J; Irigoyen, A; Linares, A; Martin, M; Ortuño, FM; Palomino, RJ; Perales, S; Prados, JC; Rojas, I; Torres, C | 1 |
| Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY | 1 |
| Balyan, R; Lockman, PR; Morikawa, A; Murphy, CG; Peereboom, DM; Samala, R; Seidman, AD; Simmons, A; Smith, QR; Steeg, PS; Tabar, V; Thorsheim, HR; Weil, RJ | 1 |
| Altundag, K; Arslan, C; Dizdar, O | 1 |
| Benedetti, JK; Blanke, CD; Gaur, R; Goldman, B; Iqbal, S; Lenz, HJ; Lowy, AM; Philip, PA; Ramanathan, RK; Wakatsuki, T; Whitehead, RP | 1 |
| Bang, YJ; Cha, Y; Han, SW; Han, W; Im, SA; Kim, TY; Noh, DY; Oh, DY; Park, IA; Seol, H | 1 |
| Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Auten, JJ; Cicci, TA; Corrigan, PA; Lowe, DK | 1 |
| Cheung, TT; Chiu, JW; Fan, ST; Leung, R; Pang, R; Poon, R; Wong, H; Yau, T | 1 |
| Fuereder, T; Hoeflmayer, D; Kornek, G; Kuehrer, I; Scheithauer, W; Stift, J; Stranzl, N | 1 |
| Ho, C; Laskin, J; Melosky, B; Murray, N; Ramsden, K; Sun, S; Zhai, Y | 1 |
| Dranitsaris, G; Lacouture, ME | 1 |
| Aprile, G; Ciuleanu, T; Csutor, Z; Federowicz, I; Fittipaldo, A; Hsu, C; Klughammer, B; Li, CP; Lipp, R; Meng, X; Moore, M; Nowara, E; Stemmer, SM; Tham, CK; Van Cutsem, E; Van Laethem, JL; Zeaiter, A | 1 |
| Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD | 1 |
| Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Iwase, T; Takahashi, S | 1 |
| Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B | 1 |
| Dawson, DW; Donahue, TR; Kadera, BE; Li, L; Nguyen, AH; Toste, PA; Wu, N | 1 |
| Blackwell, K; Diéras, V; Guardino, E; Huober, J; Krop, IE; Lin, NU; Lu, M; Miles, D; Samant, M; Welslau, M | 1 |
| Bitzer, M; Maier-Stocker, C; Malek, NP; Plentz, RR | 1 |
| Adaire, B; Cescon, TP; Choi, M; Cohen, SJ; Duncan, G; Hall, MJ; Joiner, M; Konski, A; McSpadden, E; Meropol, NJ; Meyer, JE; Philip, P; Shields, A | 1 |
| Graziani, C; Hegde, S; Saif, MW | 1 |
| Borget, I; Chabaud, S; Chouaïd, C; Crequit, J; Dô, P; Falchero, L; Fournel, P; Greillier, L; Lavolé, A; Le Caer, H; Léna, H; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenegre, A; Westeel, V; Zalcman, G | 1 |
| Arrivas Bajardi, E; Barone, C; Bencardino, K; Buonadonna, A; Cartenì, G; Comandone, A; Ferrari, D; Ferrari, S; Foa, P; Gebbia, V; Milella, M; Personeni, N; Pressiani, T; Rimassa, L; Santoro, A; Testa, A; Tronconi, MC; Zaniboni, A | 1 |
| Bai, Y; Cheng, Z; Li, S; Lv, J; Xie, L; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhong, W | 1 |
| Bennouna, J; Boyer, M; Feng, J; Geater, SL; Gorbunova, V; Hirsh, V; Hu, CP; Huang, Y; Kato, T; Lee, KH; Lee, KY; Lu, S; Massey, D; Mok, T; O'Byrne, K; Orlov, S; Popat, S; Schuler, M; Sebastian, M; Sequist, LV; Shahidi, M; Su, WC; Tsai, CM; Wu, YL; Yamamoto, N; Yang, JC; Zazulina, V; Zhou, C | 1 |
| Chen, GY; Cheng, Y; Feng, JF; Gu, CP; Huang, Y; Li, XL; Ma, LX; Shi, MQ; Song, XQ; Zhang, L; Zhang, YP; Zhao, HY; Zhou, D | 1 |
| Baroian, N; Buchner, P; Czejka, M; Dittrich, C; Sahmanovic, A; Schreiber, V | 1 |
| Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL | 1 |
| Allerton, R; Bidoli, P; Chan, S; Chmielowska, E; Ciruelos, E; Dank, M; DeSilvio, M; Fabi, A; Gori, S; Hornyak, L; Karaszewska, B; Manikhas, A; Margolin, S; Nagi, F; Nusch, A; Parikh, R; Pivot, X; Santillana, S; Semiglazov, V; Swaby, RF; Żurawski, B | 1 |
| Crinò, L; Foglietta, J; Gori, S; Metro, G | 1 |
| Buyse, M; Ding, K; Parulekar, WR; Péron, J; Roche, L; Roy, P | 1 |
| Bassermann, F; Becker, K; Eisenmenger, A; Haag, GM; Helbig, U; Karapanagiotou-Schenkel, I; Lordick, F; Lorenzen, S; Pohl, M; Riera Knorrenschild, J; Rüschoff, J; Schnoy, E; Stocker, G; Thuss-Patience, P; Weißinger, F | 1 |
| Barlesi, F; Braun, D; Debieuvre, D; Des Guetz, G; Fraboulet, G; Landre, T; Milleron, B; Molinier, O; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Uzzan, B; Vaylet, F; Westeel, V | 1 |
| Bartsch, R; Bergen, ES; Berghoff, AS; Preusser, M; Rudas, M | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Hu, HG; Huang, JJ; Shen, H; Zhao, J | 1 |
| Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Lee, KY; Li, W; Lu, S; Lungershausen, J; Palmer, M; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C | 1 |
| Julka, PK; Mallick, S; Singh, A; Venkatesulu, BP | 1 |
| Hisada, T; Imai, H; Ishihara, S; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Yamada, M; Yoshino, R | 1 |
| Beeker, A; Kordes, S; Mathôt, RA; Pollak, MN; Punt, CJ; Richel, DJ; Weterman, MJ; Wilmink, JW; Zwinderman, AH | 1 |
| Miller, K; Morant, R; Stenzl, A; Wirth, M; Zuna, I | 1 |
| Gow, CH; Liao, WY; Liu, YN; Shih, JY | 1 |
| Anthoney, DA; Backen, AC; Beare, S; Bridgewater, JA; Corrie, P; Cunningham, D; Dive, C; Duggan, M; Lopes, A; Madhusudan, S; Maraveyas, A; Morris, K; Palmer, DH; Rees, C; Ross, PJ; Steward, WP; Valle, JW; Wasan, H; Waters, JS | 1 |
| Bandai, Y; Ijichi, M; Kusaka, K; Sakata, H; Shibasaki, M; Tanabe, A; Toda, T | 1 |
| Beijnen, JH; Boss, DS; Grob, M; Huitema, AD; Keessen, M; Rehorst, H; Rosing, H; Schellens, JH; Smit, WM; Tibben, MM; van der Noll, R; Wymenga, AN | 1 |
| Kiessling, R; Lundqvist, A; Maeda, A; Nakata, M; Nakayama, E; Oka, M; Okita, R; Saisho, S; Seliger, B; Shimizu, K; Wolf, D; Yamaguchi, Y; Yasuda, K; Yukawa, T | 1 |
| Agerbaek, M; Cerbone, L; Collette, S; Daugaard, G; Marreaud, S; Sengeløv, L; Sternberg, CN; Van Herpen, C; Zhang, J | 1 |
| Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M | 1 |
| Hsiue, TR; Hwang, JS; Lai, WW; Lin, CK; Su, WC; Wang, JD; Yang, SC | 1 |
| Guzzo, T; Keefe, S; Malkowicz, SB; Mamtani, R; Narayan, V; Vaughn, DJ | 1 |
| Barrios, CH; Bines, J; Blajman, C; Capó, A; Fanelli, M; Fein, L; Gómez, HL; Ismael, G; Lerzo, G; Mano, M; Martínez-Mesa, J; Neciosup, S; Nerón, Y; Pinczowski, H; Sampaio, C; Santi, PX; Tosello, C; Varela, MS; Werutsky, G; Zarba, JJ | 1 |
| Barone, C; Basso, M; Cassano, A; Cerchiaro, E; D'Argento, E; Dadduzio, V; Martini, M; Rossi, S; Strippoli, A | 1 |
| Bradshaw-Pierce, EL; Eckhardt, SG; Eppers, S; Freas, E; Kane, MA; Kessler, ER; Leong, S; Lieu, CH; Messersmith, WA; Nallapreddy, S; O'byrant, CL; Pitts, TM; Spratlin, J; Weekes, C | 1 |
| Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM; Solca, F | 1 |
| Fahmy, O; Fend, F; Feyerabend, S; Gakis, G; Scharpf, M; Schubert, T; Schwentner, C; Stenzl, A | 1 |
| Fang, W; Tian, Y; Xue, C; Zhan, J; Zhang, J; Zhang, L; Zhao, Y | 1 |
| Hu, XC; Lin, C; Liu, MM; Tao, ZH; Wu, ZH; Zhang, J | 1 |
| Campbell, F; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Evans, A; Falk, S; Ghaneh, P; Greenhalf, W; Hickish, T; Jackson, R; Madhusudan, S; Middleton, G; Neoptolemos, JP; Palmer, DH; Propper, D; Rawcliffe, C; Ross, P; Shaw, VE; Valle, JW; Wadd, N; Wadsley, J; Wasan, H | 1 |
| Bulitta, JB; Jeong, SW; Joo, SH; Kim, S; Kim, TH; Kwon, DR; Lee, DY; Ma, E; Park, GY; Shin, BS; Shin, S; Weon, KY; Yoo, SD | 1 |
| Bergqvist, M; Bergström, S; Ekman, S; Gullbo, J; Lennartsson, J; Sooman, L | 1 |
| Ajavon-Hartmann, A; Alberts, SR; Genvresse, I; Grilley-Olson, JE; Kelly, A; Kim, RD; Peña, C; Xia, C | 1 |
| Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T | 1 |
| Abdel-Rahman, O; Elhalawani, H; Elsayed, Z | 1 |
| Baric, RS; Go, YY; Jung, E; Kim, M; Shin, JS | 1 |
| Qi, Y; Qian, S; Wu, X; Xing, K; Zhang, L; Zhang, P | 1 |
| Anthoney, A; Backen, AC; Beare, S; Bridgewater, JA; Corrie, PG; Cunningham, D; Dive, C; Duggan, M; Lopes, A; Madhusudan, S; Maraveyas, A; McNamara, MG; Palmer, DH; Rees, C; Ross, PJ; Steward, WP; Valle, JW; Wasan, H; Waters, JS | 1 |
| Bryant, A; Gaitskell, K; Goodall, RJ; Lyons, TJ; Morrison, J; Thoma, C; Wiggans, AJ | 1 |
| Abraham, RG; Dedi, B; Krucher, NA; Thomas, NA | 1 |
| Cao, Z; Ding, X; Lin, G; Liu, D; Su, B; Wang, N; Wu, C; Xu, W; Zhou, X | 1 |
| Alimoghaddam, K; Alishahi, Z; Esmaeili, F; Eyvani, H; Ghaffari, P; Ghaffari, SH; Ghavamzadeh, A; Momeny, M; Tavakkoly-Bazzaz, J; Zaghal, A | 1 |
| Birtle, A; Casbard, A; Chester, J; Crabb, S; Elliott, T; Evans, L; Griffiths, G; Huang, C; Huddart, R; Jagdev, S; Jones, R; Lester, J; Madden, TA | 1 |
| Kumar, T; Pandey, M; Soni, K | 1 |
| Al-Toubah, TE; Cao, B; Centeno, BA; Kim, J; Kim, RD; Mehta, R; Tan, ES | 1 |
| Kim, JS; Kim, SJ; Kim, T; Kim, WS; Koh, Y; Moon, JH; Park, GS; Park, J; Shin, HJ; Yang, DH; Yhim, HY | 1 |
| Cui, R; Ji, M; Jin, SY; Li, H | 1 |
| Ko, AH | 1 |
102 review(s) available for quinazolines and deoxycytidine
| Article | Year |
|---|---|
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Neoplasms; Polysaccharides, Bacterial; Prodrugs; Quinazolines; Tegafur; Thiophenes; Thymidylate Synthase; Uracil | 1995 |
The development of new chemotherapeutic agents.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasms; Pemetrexed; Quinazolines; Thiophenes; Trimetrexate | 1996 |
New anticancer drugs in Europe.
Topics: Aminopterin; Anthraquinones; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Aziridines; Bridged-Ring Compounds; Bryostatins; Camptothecin; Dacarbazine; Deoxycytidine; Distamycins; Doxorubicin; Europe; Gemcitabine; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Nitrogen Mustard Compounds; Nitrosourea Compounds; Pyrazoles; Quinazolines; Taxoids; Temozolomide; Thiophenes; Vinca Alkaloids | 1997 |
Tumor resistance to antimetabolites.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Proteins; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Amplification; Humans; Methotrexate; Mutation; Neoplasms; Quinazolines; Thiophenes | 1998 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil | 1998 |
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Glutamates; Guanine; Humans; Pemetrexed; Platinum Compounds; Pyridines; Quinazolines; Tegafur; Thiophenes; Uracil | 1999 |
New drugs in therapy of colorectal cancer: preclinical studies.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Humans; Oxidoreductases; Prodrugs; Quinazolines; Tegafur; Thiophenes; Thymidine Phosphorylase; Thymidylate Synthase; Uracil | 1999 |
Oxaliplatin: a new therapeutic option in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 1999 |
[New drugs in gastrointestinal oncology. Current status and future directions].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Taxoids; Tegafur; Thiophenes; Vinblastine; Vinorelbine | 1999 |
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?
Topics: Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunotherapy; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes | 2000 |
Novel combinations with oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2000 |
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Pyrimidines; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
[The new chemotherapy of colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Postoperative Care; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Time Factors | 2002 |
Advances in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Uracil | 2001 |
Emerging insights into the biology and therapy of malignant mesothelioma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Quinazolines; Thiophenes; Thymidylate Synthase | 2002 |
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 2; Deoxycytidine; Drug Administration Schedule; Enzyme Inhibitors; Flavonoids; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Isoenzymes; Leucovorin; Membrane Proteins; Organoplatinum Compounds; Oxaliplatin; Piperidines; Prostaglandin-Endoperoxide Synthases; Quinazolines; Thiophenes; Treatment Outcome | 2003 |
New developments in systemic chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2003 |
[Second-line treatment for advanced non-small-cell lung cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2005 |
Chemotherapy options and new advances in malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Palliative Care; Pemetrexed; Pleural Neoplasms; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2005 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Perspectives on salvage therapy for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Recent updates on the role of chemotherapy in pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines | 2005 |
Second-line chemotherapy and beyond for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Forecasting; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Pneumonectomy; Quinazolines; Salvage Therapy; Survival Rate; Taxoids; Time Factors | 2004 |
Systemic therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pemetrexed; Quinazolines | 2005 |
Erlotinib in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2005 |
[Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Quinazolines; Survival Rate | 2005 |
[Palliative chemotherapy of head and neck cancer: present status and future development].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; ErbB Receptors; Forecasting; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Systemic chemotherapy in the management of malignant peritoneal mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Peritoneal Neoplasms; Quinazolines; Thiophenes; Vinblastine; Vinorelbine | 2006 |
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2006 |
Biological agents versus chemotherapy in the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
[Molecular-based treatment concepts in advanced pancreatic cancer].
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Deoxycytidine; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Metalloproteases; Molecular Biology; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2007 |
Pancreatic cancer: an update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2007 |
Treatment of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prodrugs; Protein Kinase Inhibitors; Quinazolines; Ribonucleotide Reductases; Survival Rate | 2007 |
Her signaling in pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Epidermal Growth Factor; Erlotinib Hydrochloride; Gemcitabine; Humans; Lapatinib; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
[Treatments of pancreatic cancer from the standpoint of medical oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Quinazolines; Survival Rate; Tegafur | 2007 |
Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pancreatic Neoplasms; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2008 |
[Chemotherapy for pancreatic cancer].
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Benzenesulfonates; Bevacizumab; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2008 |
Pancreatic cancer--is the wall crumbling?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorouracil; Forecasting; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
[Pancreatic cancer: ten years of systemic therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines | 2008 |
Erlotinib-induced acute hepatitis in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Liver; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Dioxoles; Diphtheria Toxin; Drug Resistance, Neoplasm; Drugs, Investigational; Epothilones; Female; Furans; Gemcitabine; Glutamates; Guanine; Humans; Interleukin-2; Ketones; Lapatinib; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Recombinant Fusion Proteins; Tetrahydroisoquinolines; Trabectedin; Vinblastine; Vinorelbine | 2008 |
New directions in the management of advanced pancreatic cancer: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Quinazolines | 2008 |
Novel advances in pancreatic cancer treatment.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Delivery Systems; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2008 |
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Time Factors; Trastuzumab | 2008 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Skin Diseases; Treatment Outcome | 2009 |
Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2008 |
Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Consensus Development Conferences as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lapatinib; Paclitaxel; Publication Bias; Publishing; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Time; Trastuzumab | 2008 |
[Treatment of advanced pancreatic carcinoma].
Topics: Antineoplastic Agents; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Platinum; Quinazolines; Terminal Care | 2008 |
[Medical-oncological aspects in the treatment of pancreatic cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Survival Rate | 2009 |
First-line therapeutic strategies in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex | 2008 |
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Purines; Quinazolines; RNA, Small Interfering; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gene Expression; Humans; Lapatinib; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2009 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2 | 2009 |
Lapatinib in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Trastuzumab | 2009 |
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2009 |
Current combination chemotherapy regimens for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Breast Neoplasms; Capecitabine; Cytotoxins; Deoxycytidine; Diarrhea; Drug Delivery Systems; Epothilones; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Signal Transduction; Skin Diseases; Trastuzumab | 2009 |
[Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Trastuzumab; Treatment Outcome | 2009 |
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Rectal Neoplasms; Treatment Failure | 2010 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
[New data on pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2010 |
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Interactions; Epothilones; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Peripheral Nervous System Diseases; Quinazolines; Treatment Failure; Treatment Outcome; Tubulin Modulators | 2010 |
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cetuximab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Signal Transduction; Survival Analysis; Translocation, Genetic | 2010 |
Challenges of drug resistance in the management of pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Tumor Microenvironment | 2010 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triazoles | 2011 |
The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2011 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
[Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
Developments in metastatic pancreatic cancer: is gemcitabine still the standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib | 2012 |
Novel agents in early phase clinical studies on refractory pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Ipilimumab; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents | 2012 |
Adjuvant therapy for pancreas adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2013 |
New insights and emerging therapies for breast cancer brain metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Paclitaxel; Peptides; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy; Receptor, ErbB-2; Trastuzumab | 2012 |
Systemic therapy of advanced pancreatic cancer: has the landscape changed?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
New developments in pancreatic cancer treatment.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
[Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
First-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Trastuzumab emtansine in breast cancer.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Heart Diseases; Humans; Neoplasms; Quinazolines; Retrospective Studies; Thiophenes | 2013 |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2013 |
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Survival; Taxoids | 2013 |
[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gene Amplification; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neovascularization, Pathologic; Prognosis; Quinazolines; Receptor, ErbB-2; Taxoids; TOR Serine-Threonine Kinases; Trastuzumab | 2013 |
[Current status and future directions of chemotherapy for pancreatic cancer].
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Tegafur | 2013 |
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2014 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Docetaxel; Enzyme Induction; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Nicotine; Paclitaxel; Polycyclic Aromatic Hydrocarbons; Quinazolines; Smoking; Taxoids | 2014 |
Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2014 |
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kidney Failure, Chronic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Renal Dialysis; Taxoids | 2018 |
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Tegafur | 2018 |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Progression-Free Survival; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2018 |
Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Oxaliplatin; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2020 |
180 trial(s) available for quinazolines and deoxycytidine
| Article | Year |
|---|---|
Activity of raltitrexed and gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Quinazolines; Thiophenes; Treatment Outcome; Vomiting | 2003 |
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Time Factors; Treatment Outcome | 2003 |
A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis | 2003 |
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Quinazolines; Reference Values; Survival Analysis; Treatment Outcome | 2004 |
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Drug Interactions; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines; Treatment Outcome | 2004 |
A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Survival Rate; Thiophenes | 2005 |
Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Belgium; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2004 |
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2005 |
Brief communication: a new combination in the treatment of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Survival Rate | 2005 |
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Rectal Neoplasms | 2006 |
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Quinazolines; Salvage Therapy; Survival Analysis; Thiophenes | 2006 |
A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Survival Rate; Tegafur | 2006 |
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis | 2006 |
Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gefitinib; Gemcitabine; Humans; Interleukin-8; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Radiotherapy Dosage; Vascular Endothelial Growth Factor A | 2006 |
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Heart Diseases; Humans; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2006 |
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Probability; Prognosis; Quinazolines; Risk Assessment; Statistics, Nonparametric; Survival Analysis | 2007 |
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; International Agencies; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate | 2007 |
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2007 |
A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Taxoids | 2006 |
A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Rate | 2007 |
Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2007 |
Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Child; Child, Preschool; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines | 2007 |
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2008 |
A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Quinazolines; Treatment Outcome; Urologic Neoplasms; Urothelium | 2008 |
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; Radiography; ras Proteins; Risk Assessment; Risk Factors; Smoking; Surveys and Questionnaires; Switzerland; Treatment Outcome | 2008 |
Improving treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Trastuzumab | 2008 |
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines | 2008 |
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines; Taxoids; Treatment Outcome | 2008 |
Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Routes; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Salvage Therapy; Treatment Outcome | 2008 |
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis | 2008 |
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2009 |
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rat
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Research Design | 2008 |
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Recurrence; Survival Analysis | 2008 |
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Diseases; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Genes, ras; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins; Receptor, ErbB-2; Survival Analysis | 2008 |
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Approval; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; United States; United States Food and Drug Administration; Young Adult | 2008 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines | 2009 |
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazoles; Quinazolines; Risk; Sulfonamides | 2008 |
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National C
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2009 |
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Surveys and Questionnaires | 2009 |
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Quinazolines; Urologic Neoplasms | 2009 |
Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2009 |
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2009 |
Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Taxoids | 2009 |
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Maximum Tolerated Dose; Medication Adherence; Middle Aged; Quinazolines | 2009 |
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2009 |
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreas, Exocrine; Pancreatic Neoplasms; Prospective Studies; Quinazolines | 2010 |
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Quinazolines; Receptor, ErbB-2; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2 | 2009 |
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunohistochemistry; Isoflavones; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2011 |
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Taxoids | 2010 |
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperidines; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cross-Over Studies; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver; Middle Aged; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Ventricular Function, Left | 2010 |
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Canada; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Dosage; Humans; Mutation; Pancreatic Neoplasms; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2010 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival; Treatment Outcome | 2011 |
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Canada; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Treatment Outcome; Tumor Burden | 2012 |
Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Adenosquamous; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2011 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Gene Amplification; Genes, ras; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2012 |
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Exanthema; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Remission Induction | 2011 |
Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Infections; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Pancreatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Time Factors; Tumor Burden; Vomiting | 2012 |
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Europe; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Treatment Outcome | 2011 |
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Fluorouracil; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Quinazolines | 2011 |
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Activation; Exons; Female; Fluorouracil; Follow-Up Studies; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Confidence Intervals; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lapatinib; Models, Economic; Probability; Quality-Adjusted Life Years; Quinazolines; State Medicine; Trastuzumab; United Kingdom; Women's Health | 2012 |
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Topotecan | 2011 |
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prodrugs; Quinazolines; Treatment Outcome; Young Adult | 2011 |
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2011 |
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Hypertension; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Niacinamide; Oligonucleotides; Quinazolines; Treatment Outcome; Venous Thrombosis; Vomiting; Young Adult | 2011 |
Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2011 |
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Area Under Curve; Asian People; Capecitabine; Cisplatin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Hyponatremia; Japan; Male; Metabolic Clearance Rate; Middle Aged; Neutropenia; Oxonic Acid; Quinazolines; Stomach Neoplasms; Tegafur; Treatment Outcome; Tumor Burden | 2012 |
Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Genes, ras; Humans; Middle Aged; Mutation; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2011 |
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Piperidines; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFP
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2011 |
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Placebos; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk | 2012 |
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2012 |
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2012 |
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Pulmonary Embolism; Quinazolines; Treatment Outcome | 2012 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Europe; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Treatment Outcome | 2012 |
A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2012 |
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Treatment Failure | 2012 |
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Treatment Outcome | 2012 |
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, IGF Type 1; Sorafenib | 2012 |
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Topics: Administration, Metronomic; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2013 |
Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotoxins; Lapatinib; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Early Termination of Clinical Trials; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2012 |
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Early Detection of Cancer; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prospective Studies; Quinazolines; Treatment Outcome; Young Adult | 2012 |
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2013 |
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2012 |
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Erlotinib Hydrochloride; France; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Monte Carlo Method; Multivariate Analysis; Prospective Studies; Quinazolines; Taxoids | 2012 |
Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2012 |
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Survival Rate; Trastuzumab | 2012 |
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Proportional Hazards Models; Pyridines; Quinazolines; Survival Analysis | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Young Adult | 2012 |
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Melanoma; Middle Aged; Quinazolines; Receptor, IGF Type 1; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2013 |
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Central Nervous System; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2 | 2013 |
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Salvage Therapy; Surveys and Questionnaires | 2012 |
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins | 2013 |
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dyspnea; Fatigue; Female; Gemcitabine; Humans; Hypothyroidism; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Stomatitis; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Stomatitis; Vomiting | 2012 |
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Socie
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Outcome | 2014 |
Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Injections, Intralesional; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Treatment Failure | 2013 |
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Predictive Value of Tests; Proteomics; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2013 |
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Carboplatin; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Models, Economic; Quinazolines; Time Factors | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2013 |
Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prospective Studies; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quality of Life; Quinazolines; Radiotherapy, Intensity-Modulated | 2013 |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Patient Selection; Proportional Hazards Models; Prospective Studies; Quinazolines; Time Factors; Treatment Outcome | 2013 |
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Calcium-Binding Proteins; Camptothecin; Capecitabine; Colorectal Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; EGF Family of Proteins; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; MicroRNAs; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaloacetates; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Nausea; Quinazolines; Quinolines; Receptor, ErbB-2; Treatment Outcome; Vomiting | 2013 |
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.
Topics: Adult; Aged; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; EGF Family of Proteins; Erlotinib Hydrochloride; Female; Fluorouracil; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Mutation; Neoplasm Metastasis; Oxaloacetates; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Transforming Growth Factor alpha | 2013 |
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Proteins; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Organoplatinum Compounds; Oxaloacetates; Placebos; Predictive Value of Tests; Prognosis; Quinazolines; Survival Analysis | 2013 |
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Health Status; Humans; Lapatinib; Maytansine; Medication Adherence; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Self Report; Surveys and Questionnaires; Time Factors; Trastuzumab; Treatment Outcome | 2014 |
Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Preoperative Care; Quinazolines; Radiotherapy Dosage; Rectal Neoplasms | 2014 |
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2014 |
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Risk Factors; Thailand; Time Factors; Treatment Outcome | 2014 |
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Treatment Outcome | 2014 |
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Piperidines; Placebos; Quinazolines; Survival Rate | 2014 |
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure | 2011 |
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Treatment Outcome | 2013 |
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Topics: Adolescent; Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Drug Administration Schedule; Equilibrative Nucleoside Transporter 1; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Prospective Studies; Quinazolines; Rabbits; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.
Topics: Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphopenia; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Quinazolines; Radiography; Severity of Illness Index; Survival Analysis; Tumor Burden | 2014 |
Prognostic and predictive value of metabolic tumor volume on (18)F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gemcitabine; Glycolysis; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Quinazolines; Survival Analysis; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate | 2014 |
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Insulin-Like Growth Factor I; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome | 2014 |
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Models, Biological; Quinazolines; Risk Factors; ROC Curve; Skin Neoplasms | 2014 |
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2014 |
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Sulfonamides; Taxoids; Temozolomide; Young Adult | 2015 |
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paresthesia; Quinazolines; Quinolines; Receptor, ErbB-2; Syndrome; Trastuzumab; Treatment Outcome | 2014 |
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Lapatinib; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Young Adult | 2015 |
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2014 |
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Health Care Costs; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Prospective Studies; Quality-Adjusted Life Years; Quinazolines; Survival Analysis | 2014 |
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Piperidines; Quinazolines | 2015 |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Survival Rate | 2015 |
Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers; Capecitabine; China; Deoxycytidine; Disease-Free Survival; Drug Synergism; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Fluorouracil; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines; Thymidine Phosphorylase; Treatment Outcome | 2015 |
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer.
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Treatment Outcome | 2015 |
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Gene Dosage; Germany; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Time Factors; Treatment Outcome | 2015 |
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quality of Life; Quinazolines; Treatment Outcome | 2015 |
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Topics: Academic Medical Centers; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Metformin; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Netherlands; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transition
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2016 |
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Treatment Outcome; United Kingdom | 2015 |
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Fatigue; Female; Gemcitabine; Humans; Lapatinib; Middle Aged; Quinazolines | 2015 |
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Febrile Neutropenia; Female; Gemcitabine; Humans; International Cooperation; Lapatinib; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Renal Insufficiency; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lapatinib; Lymph Node Excision; Male; Maximum Tolerated Dose; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2016 |
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Quinazolines; Treatment Outcome | 2016 |
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Prognosis; Quinazolines; Survival Rate | 2017 |
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Treatment Outcome | 2018 |
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Keratin-18; Male; Middle Aged; Neoplasm Proteins; Neoplastic Cells, Circulating; Quinazolines; Treatment Outcome; United Kingdom; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Double-Blind Method; Drug Combinations; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Piperidines; Quinazolines; Treatment Outcome | 2020 |
Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Precision Medicine; Progression-Free Survival; PTEN Phosphohydrolase; Pyrimidines; Quinazolines | 2021 |
Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.
Topics: Deoxycytidine; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Pyrimidines; Quinazolines; Treatment Outcome | 2021 |
226 other study(ies) available for quinazolines and deoxycytidine
| Article | Year |
|---|---|
Topoisomerase I inhibitors and other new cytotoxic drugs.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aziridines; Camptothecin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Organoplatinum Compounds; Quinazolines; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors | 1995 |
Colon cancer: new drug options improve on 5-FU.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1998 |
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cell Survival; Deoxycytidine; Equilibrative Nucleoside Transport Proteins; Flow Cytometry; Fluoresceins; Fluorescent Dyes; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms; Purine Nucleosides; Quinazolines; Thiophenes; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
New antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Deoxycytidine; Dioxolanes; Drugs, Investigational; Emtricitabine; Furans; Guanosine; HIV Fusion Inhibitors; Humans; Imidazoles; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Prodrugs; Protease Inhibitors; Pyridines; Pyrones; Quinazolines; Reverse Transcriptase Inhibitors; Sulfonamides; Sulfur Compounds; Tenofovir | 2001 |
25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2001 |
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2002 |
Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Androstadienes; Animals; Antineoplastic Agents; Apoptosis; Deoxycytidine; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique, Indirect; Gemcitabine; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, SCID; Microscopy, Fluorescence; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Wortmannin | 2002 |
[New therapeutic options for mesothelioma].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Folic Acid Antagonists; France; Gemcitabine; Humans; Mesothelioma; Mitomycin; Neoplasm Staging; Patient Selection; Pneumonectomy; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Risk Factors; Survival Analysis; Thiophenes; Treatment Outcome; Vindesine | 2002 |
27th ESMO Congress, Nice, 18-22 October 2002. Iressa disappoints in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Congresses as Topic; Deoxycytidine; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Treatment Failure | 2003 |
Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gefitinib; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Lung; Lung Neoplasms; Quinazolines; Tomography, X-Ray Computed | 2003 |
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Primers; Floxuridine; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Models, Chemical; Polymerase Chain Reaction; Pyrimidines; Quinazolines; RNA; RNA, Messenger; Time Factors; Transcription, Genetic | 2003 |
Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Taxoids | 2003 |
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Time Factors; Xenograft Model Antitumor Assays | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Synergistic antitumor activity of capecitabine in combination with irinotecan.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Thiophenes | 2005 |
Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Thiophenes | 2005 |
Innovative therapy for patients with brain metastases: oral treatments.
Topics: Administration, Oral; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Quinazolines; Temozolomide | 2004 |
Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines | 2005 |
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Endothelial Cells; Gemcitabine; Humans; Indoles; Oxindoles; Piperidines; Propionates; Pyrroles; Quinazolines; Thromboplastin | 2005 |
[Chemotherapy of pancreatic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2005 |
Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Polymerase Chain Reaction; Quinazolines | 2005 |
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Thymidine Phosphorylase; Xenograft Model Antitumor Assays | 2006 |
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Tegafur; Thiophenes; Treatment Outcome; Uracil | 2005 |
Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Deoxycytidine; Drug Administration Schedule; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Quinazolines; Tumor Cells, Cultured | 2006 |
Erlotinib or capecitabine with gemcitabine in pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2006 |
Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gemcitabine; Genes, erbB-1; Genes, ras; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies | 2006 |
Serum tumor markers for pancreatic cancer: the dawn of new era?
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; DNA Methylation; DNA, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proteomics; Quinazolines; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Cohort Studies; Data Interpretation, Statistical; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gastrointestinal Tract; Humans; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research Design | 2006 |
Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Genistein; Humans; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Deoxycytidine Kinase; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gemcitabine; Gene Expression Profiling; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Piperidines; Polymerase Chain Reaction; Predictive Value of Tests; Quinazolines; Radiation, Ionizing; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Transplantation, Heterologous | 2006 |
Targeted therapy for metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2006 |
Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Fluorouracil; Gene Deletion; Genotype; Heterozygote; Humans; Models, Statistical; Mutation; Polymorphism, Genetic; Quinazolines; Sequence Analysis, DNA; Thiophenes; Thymidylate Synthase; Treatment Outcome | 2007 |
Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; MAP Kinase Kinase 4; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Survival Rate; Transplantation, Heterologous; Vinblastine; Vinorelbine | 2007 |
Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gefitinib; Gemcitabine; Humans; In Vitro Techniques; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Stomach Neoplasms; Tegafur; Trastuzumab; Uracil; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2007 |
Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Urinary Bladder Neoplasms | 2007 |
Lapatinib plus capecitabine in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2007 |
Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Taiwan; Taxoids; Treatment Outcome | 2006 |
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Quinazolines; Regional Blood Flow; Signal Transduction; Skin; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Mice; Mice, Nude; Quinazolines; Rats; Transplantation, Heterologous | 2007 |
Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.
Topics: Adenocarcinoma; Aged; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Neoplasm Proteins; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Exanthema; Gemcitabine; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prednisolone; Quinazolines; Radiography | 2007 |
Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quality-Adjusted Life Years; Quinazolines; Survival Analysis; United States | 2007 |
Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase.
Topics: Blotting, Western; Capecitabine; Cell Cycle; Cell Line; Deoxycytidine; DNA; DNA Primers; DNA Repair; Fluorouracil; Green Fluorescent Proteins; Humans; Mass Spectrometry; Quinazolines; Thiophenes; Thymidylate Synthase; Uracil; Uracil-DNA Glycosidase | 2008 |
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2007 |
Gemcitabine resistance in a highly metastatic subpopulation of a pulmonary adenocarcinoma cell line resistant to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; RNA, Small Interfering; Transfection | 2007 |
Finding clinical meaning in cancer data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Data Interpretation, Statistical; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Evidence-Based Medicine; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sample Size; Survival Analysis | 2007 |
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diarrhea; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2008 |
Tumor resensitization to erlotinib following brief substitution of cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Neoplasms; Cetuximab; Deoxycytidine; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Treatment of breast cancer with trastuzumab during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Lapatinib; Lung Neoplasms; Mastectomy, Modified Radical; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Quinazolines; Trastuzumab | 2008 |
Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Leucovorin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Male; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Philadelphia Chromosome; Quinazolines; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thiophenes | 2008 |
Cerebellar toxicity with capecitabine in a patient with metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cerebellar Ataxia; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines | 2008 |
Unilateral blindness as a presenting symptom of lung cancer treated with erlotinib.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
Ten years of HER2-directed therapy: still questions after all these years.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Forecasting; Humans; Lapatinib; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2009 |
Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.
Topics: Aged; Budgets; Deoxycytidine; Drug Costs; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Models, Economic; Neoplasm Staging; Outcome Assessment, Health Care; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Ribonucleotide Reductases; Severity of Illness Index; Survival Rate; United States | 2008 |
Drug development in the targeted therapy era.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disclosure; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Lapatinib; Maximum Tolerated Dose; Quinazolines; Receptor, ErbB-2 | 2008 |
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Immunoblotting; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy; Xenograft Model Antitumor Assays | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 2008 |
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quality of Life; Quinazolines; Sensitivity and Specificity | 2009 |
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Neoadjuvant Therapy; Pemetrexed; Pleural Neoplasms; Pneumonectomy; Quinazolines; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Thiophenes; Vinblastine; Vinorelbine | 2009 |
Generating genome-scale candidate gene lists for pharmacogenomics.
Topics: Anticoagulants; Antineoplastic Agents; Area Under Curve; Carboplatin; Deoxycytidine; Gefitinib; Gemcitabine; Gene Expression Regulation; Genes; Genome, Human; Humans; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Quinazolines; Warfarin | 2009 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Lapatinib: new drug. For some women with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Drug Approval; Female; Fluorouracil; France; Humans; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines | 2009 |
The "win-win" initiative: a global, scientifically based approach to resource sparing treatment for systemic breast cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Pharmacogenetics; Quinazolines; Trastuzumab | 2009 |
Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment.
Topics: Androgens; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gemcitabine; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Time Factors; Tyrphostins | 2009 |
Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Germany; Health Care Surveys; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Guidelines as Topic; Prognosis; Quinazolines; Radiotherapy Dosage; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome | 2009 |
Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Mucin-1; Quinazolines; Receptor, ErbB-2; Thrombocytopenia; Trastuzumab | 2009 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Papillary; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2010 |
Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate; Time Factors | 2009 |
A patient of situs ambiguus with pancreatic head cancer successfully treated with gemcitabine and erlotinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Situs Inversus; Treatment Outcome | 2011 |
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Health Services Accessibility; Humans; Lapatinib; Middle Aged; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome; United Kingdom | 2010 |
Targeted HER2 treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2010 |
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Deoxycytidine; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Indoles; Mice; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2010 |
Stromal depletion goes on trial in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Hedgehog Proteins; Humans; Off-Label Use; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Survival Analysis; United States | 2010 |
Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Killer Cells, Natural; Lapatinib; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Trastuzumab | 2011 |
Any progress in pancreatic cancer? Well, but progress for Acta Oncologica.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Congresses as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Journalism, Medical; Pancreatic Neoplasms; Quinazolines; Research Design; Treatment Failure | 2010 |
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
Topics: 3T3 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Immunoblotting; In Situ Hybridization, Fluorescence; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Thymidine Phosphorylase; Vascular Endothelial Growth Factor A | 2010 |
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Erlotinib Hydrochloride; Gemcitabine; Genetic Engineering; Humans; Lung Neoplasms; Mice; Mutation; Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Analysis; Vascular Endothelial Growth Factor A | 2010 |
A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Quinazolines | 2011 |
Novel targeted therapies in inflammatory breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Delivery Systems; Fluorouracil; Humans; Inflammation; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2010 |
NICE rejects drug for metastatic breast cancer because of cost and poor efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Drug Recalls; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quality-Adjusted Life Years; Quinazolines; Treatment Outcome; United Kingdom | 2010 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids | 2010 |
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome; Young Adult | 2011 |
Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Gemcitabine; Gene Expression; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rad51 Recombinase; RNA, Small Interfering; Transfection; Ubiquitin | 2010 |
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorouracil; Gene Expression Profiling; Genetic Markers; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
[Efficacy of gemcitabine combined with erlotinib in patients with advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Health Status Indicators; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2010 |
High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cell Proliferation; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Logistic Models; Middle Aged; Quinazolines; Receptor, ErbB-2; Republic of Korea; Risk Assessment; Risk Factors; Time Factors; Transforming Growth Factor alpha; Treatment Outcome; Up-Regulation | 2011 |
Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Mutation; Positron-Emission Tomography; Quinazolines; Treatment Outcome | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Erlotinib resistance is altered after gemcitabine chemotherapy for recurrent non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2011 |
[Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2010 |
One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Catheter Ablation; Cetuximab; Cytokine-Induced Killer Cells; Deoxycytidine; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Oxaloacetates; Positron-Emission Tomography; Quality of Life; Quinazolines; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2010 |
Pancreatic cancer: will incremental advances begin to make a difference?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Failure | 2010 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Interstitial lung disease under erlotinib plus gemcitabine for pancreatic carcinoma: a therapeutic dilemma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2011 |
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Acinar Cell; Cell Line, Tumor; Cell Movement; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Sequence Deletion | 2011 |
Microcystic/reticular schwannoma of the pancreas: a potential diagnostic pitfall.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Deoxycytidine; Diagnostic Errors; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neurilemmoma; Pancreatectomy; Pancreatic Neoplasms; Quinazolines | 2011 |
Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2012 |
Analysis of tumor burden versus progression-free survival for Phase II decision making.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Trastuzumab; Tumor Burden | 2011 |
Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Dasatinib; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; src-Family Kinases; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
Response to combined molecular targeting: defining the role of P-STAT3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Mutation; Nitriles; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; RNA, Small Interfering; Tyrphostins | 2011 |
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase B; Aurora Kinases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Nude; Organophosphates; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Quinazolines; Xenograft Model Antitumor Assays | 2011 |
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2011 |
Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; GATA6 Transcription Factor; Gemcitabine; Gene Expression Profiling; Humans; Male; Mice; Pancreatic Neoplasms; Pharmacogenetics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Pancreatic adenocarcinoma-associated polymyositis treated with corticosteroids along with cancer specific treatment: case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glucocorticoids; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymyositis; Quinazolines; Radionuclide Imaging | 2011 |
A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.
Topics: Animals; Benzamides; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cisplatin; Culture Media; Deoxycytidine; Dioxoles; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gemcitabine; Humans; Mice; Mice, Transgenic; Pancreatic Neoplasms; Quinazolines; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Microenvironment | 2011 |
Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer.
Topics: Antimetabolites, Antineoplastic; Chi-Square Distribution; Combined Modality Therapy; Contrast Media; Deoxycytidine; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiography, Interventional; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2011 |
Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Capecitabine; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thymidine Phosphorylase; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2012 |
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; ErbB Receptors; Female; Floxuridine; Fluorouracil; Gefitinib; Gene Expression Regulation, Enzymologic; Humans; Inhibitory Concentration 50; Methotrexate; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Thymidine Phosphorylase; Thymidylate Synthase | 2012 |
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclin D1; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2012 |
Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Area Under Curve; Combined Modality Therapy; Deoxycytidine; Duodenum; Erlotinib Hydrochloride; Female; Gastrointestinal Tract; Gemcitabine; Humans; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Quinazolines; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Risk Factors | 2012 |
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Length of Stay; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quinazolines; Survival Rate; Taxoids | 2012 |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Blotting, Western; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Biliary-tract cancer: improving therapy by adding molecularly targeted agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2012 |
[A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines | 2011 |
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; NF-kappa B; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Quinazolines; Signal Transduction | 2012 |
Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Capecitabine; Carcinoma; Deoxycytidine; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lapatinib; Liver Neoplasms; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Scalp; Skin Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Combination therapy with gemcitabine (GEM) and erlotinib (E) in exocrine pancreatic cancer under special reference to RASH and the tumour marker CA19-9.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Pancreatic Neoplasms; Quinazolines | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Community Health Services; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Tennessee; Time Factors; Treatment Outcome | 2013 |
[A case of HER2-positive breast cancer receiving lapatinib+capecitabine chemotherapy with ventriculoperitoneal shunting for hydrocephalus associated with brain metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Hydrocephalus; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Ventriculoperitoneal Shunt | 2012 |
Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Lapatinib; Leucovorin; Oligodeoxyribonucleotides; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Thionucleotides | 2012 |
Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Failure; Vinblastine; Vinorelbine | 2012 |
Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Costs and Cost Analysis; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; France; Health Services; Humans; Lapatinib; Middle Aged; Models, Econometric; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; ErbB Receptors; Fluorouracil; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Survivin | 2012 |
A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cisplatin; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Quinazolines; Small Cell Lung Carcinoma; Taxoids | 2012 |
Ulcerated plaques in the pelvic region of an adult female.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Genital Neoplasms, Female; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Skin Neoplasms; Skin Ulcer | 2012 |
Primary systemic treatment of breast-cancer brain metastases.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Male; Medication Adherence; Medication Errors; Middle Aged; Patient Compliance; Pilot Projects; Prognosis; Prospective Studies; Quinazolines | 2013 |
[Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2012 |
[A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Remission Induction | 2012 |
Indian drug maker cuts price of three cancer drugs by between 50% and 63%.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Docetaxel; Drug Costs; Drug Industry; Erlotinib Hydrochloride; Fluorouracil; Humans; India; Quinazolines; Taxoids | 2012 |
[Perforation of the nasal septum: a rare complication of bevacizumab].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Middle Aged; Nasal Septal Perforation; Neoplasm Proteins; Pemetrexed; Quinazolines; Respiratory Insufficiency; Salvage Therapy; Vascular Endothelial Growth Factor A | 2012 |
Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prevalence; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Turkey | 2012 |
HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Humans; Injections, Intravenous; Kidney Neoplasms; Lapatinib; Male; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Brain metastases from HER2-positive breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Brain metastases from HER2-positive breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Brain metastases from HER2-positive breast cancer - authors' reply.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Flow Cytometry; Gemcitabine; Immunoenzyme Techniques; Immunoprecipitation; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Survival Rate; Tumor Cells, Cultured | 2013 |
Lack of improvement in overall survival with gemcitabine/ erlotinib maintenance and its relationship with pemetrexed use in the second-line setting.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
For breast cancer patients with brain mets, new drug combo may be option.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Treatment Outcome | 2012 |
Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Mitochondria; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor | 2012 |
Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Biopsy; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Immunohistochemistry; Leucine; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Unknown Primary; Point Mutation; Quinazolines; Tomography, X-Ray Computed | 2013 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
Reply to N. Singh et al.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crown Ethers; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prognosis; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2013 |
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Hypertension; Lung Neoplasms; Middle Aged; Oxonic Acid; Pemetrexed; Plasma; Purpura, Thrombotic Thrombocytopenic; Pyridines; Quinazolines; Recombinant Proteins; Solubility; Taxoids; Tegafur; Thrombomodulin | 2013 |
Hypertriglyceridemia in patients with metastatic breast cancer and treatment with capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diabetes Mellitus; Dyslipidemias; Female; Fluorouracil; Humans; Hypertriglyceridemia; Israel; Lapatinib; Middle Aged; Multivariate Analysis; Quinazolines; Regression Analysis; Retrospective Studies; Risk Factors | 2013 |
Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Peptide Fragments; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Telomerase; Treatment Outcome; Vaccines | 2013 |
[A case of pancreatic body cancer with multiple liver metastases experiencing long-term response by gemcitabine plus erlotinib therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Time Factors | 2013 |
[Combined therapy of lapatinib and capecitabine effective against local recurrence of breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Recurrence; Tomography, X-Ray Computed | 2013 |
[Current possibilities of targeted therapy in the treatment of breast cancer with overexpression of HER-2/neu and metastatic lesions in the brain].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Up-Regulation | 2013 |
In vitro effects of lapatinib with gemcitabine for pancreatic cancer cells.
Topics: Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Lapatinib; Pancreatic Neoplasms; Quinazolines; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2013 |
ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbamates; Carboxylesterase; Cell Line, Tumor; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Hydrolysis; Mice; Mice, Inbred BALB C; Neoplasms; Quinazolines; Thymidine Phosphorylase | 2013 |
Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Knockdown Techniques; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Tyrphostins; Xenograft Model Antitumor Assays | 2013 |
Erlotinib-induced thrombocytosis in patients with recurrence of pancreatic cancer after distal pancreatectomy.
Topics: Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Platelet Count; Quinazolines; Splenectomy; Thrombocytosis | 2013 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2014 |
Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer.
Topics: Antineoplastic Agents; Articulation Disorders; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines | 2015 |
Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Inhibitory Concentration 50; Nucleoside Transport Proteins; Piperidines; Quinazolines; Saccharomyces cerevisiae; Uridine | 2014 |
Early-onset brain metastases in a breast cancer patient after pathological complete response to neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2013 |
Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate | 2014 |
Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Substitution; Fluorouracil; Heart Diseases; Humans; Irinotecan; Middle Aged; Quinazolines; Thiophenes | 2014 |
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Giant Cell Tumors; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
[Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quinazolines | 2013 |
Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Eruptions; Drug Evaluation; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2014 |
Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lymphocytes; Male; Neutrophils; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quinazolines; Survival Analysis; Tegafur; Treatment Outcome | 2014 |
Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2014 |
Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Urothelium | 2014 |
[A case of trastuzumab-resistant breast cancer responding to lapatinib/capecitabine therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Trastuzumab | 2014 |
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2014 |
Serum cytokine profile in patients with pancreatic cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Comorbidity; Cytokines; Deoxycytidine; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Predictive Value of Tests; Quinazolines; ROC Curve; Sensitivity and Specificity; Smoking; Tumor Microenvironment | 2014 |
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Quinazolines; Republic of Korea; Retrospective Studies; Survivors; Treatment Outcome | 2014 |
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Brain Chemistry; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prospective Studies; Quinazolines | 2015 |
Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Taxoids; Treatment Outcome | 2014 |
Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.
Topics: Biomarkers, Tumor; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Molecular Targeted Therapy; Neoplasm Staging; Pancreatic Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2014 |
Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; British Columbia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Therapy; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum Compounds; Quinazolines; Retrospective Studies; Sex Factors; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Eruptions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2014 |
Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Proto-Oncogene Proteins c-cbl; Quinazolines; RNA, Small Interfering | 2015 |
Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Combined Modality Therapy; Deoxycytidine; Endoscopy, Digestive System; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gastritis; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Injuries; Radiography; Thymidine Phosphorylase; Withholding Treatment | 2014 |
Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Proliferation; Central Nervous System; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2 | 2015 |
A simple method for comparing enzymatic capecitabine activation in various mono- and combination chemotherapies.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Carboxylesterase; Cytidine Deaminase; Deoxycytidine; Enzyme Activation; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2015 |
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2014 |
Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Central Nervous System Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Maytansine; Quinazolines | 2015 |
Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Crown Ethers; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Targeted Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
Non small cell carcinoma of lung with metachronous breast metastasis and cardiac tamponade: Unusual presentation of a common cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Non-Small-Cell Lung; Cardiac Tamponade; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasms, Second Primary; Quinazolines; Radiography | 2015 |
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2015 |
Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Exons; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Pemetrexed; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine | 2015 |
[A Case of Effective Whole-Brain Irradiation and Lapatinib/Capecitabine Combination Therapy for HER2-Positive Breast Cancer with Multiple Brain Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Remission Induction | 2015 |
Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Killer Cells, Natural; Lung Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Protein Kinase Inhibitors; Quinazolines | 2015 |
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab | 2015 |
Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Prospective Studies; Quality of Life; Quinazolines; Sickness Impact Profile; Surveys and Questionnaires; World Health Organization | 2016 |
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gemcitabine; Gene Deletion; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Taxoids | 2016 |
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.
Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Crizotinib; Cyclic S-Oxides; Deoxycytidine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Ligands; MAP Kinase Signaling System; Mutation; Pancreatic Neoplasms; Phenotype; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT3 Transcription Factor | 2016 |
Ten Years of Complete Remission of Pulmonary Metastasis after Post-Cystectomy Palliative Cisplatin-Gemcitabine Chemotherapy with Gefitinib for Muscle Invasive Bladder Cancer: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Quinazolines; Urinary Bladder Neoplasms | 2016 |
In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship | 2016 |
Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzodioxoles; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Focal Adhesion Kinase 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Inhibitor of Apoptosis Proteins; JNK Mitogen-Activated Protein Kinases; Matrix Metalloproteinase 3; Octamer Transcription Factor-3; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; RNA, Small Interfering; src-Family Kinases; Survivin; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2016 |
Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biological Availability; Biotransformation; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Gemcitabine; Male; Plant Extracts; Plants, Medicinal; Protective Agents; Quinazolines; Rats; Rats, Sprague-Dawley | 2017 |
Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gefitinib; Gemcitabine; Humans; Piperidones; Proteasome Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Vinblastine; Vinorelbine | 2017 |
Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro.
Topics: Antiviral Agents; Benzodioxoles; Cell Line; Cross Infection; Deoxycytidine; DNA Replication; Drug Discovery; Enzyme Inhibitors; Gemcitabine; Humans; Middle East Respiratory Syndrome Coronavirus; Quinazolines; Small Molecule Libraries; src-Family Kinases; Virus Replication | 2018 |
A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2018 |
Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreas; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Retinoblastoma Protein; RNA, Small Interfering; STAT3 Transcription Factor | 2019 |
Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Crown Ethers; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; G2 Phase Cell Cycle Checkpoints; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; RNA, Small Interfering | 2019 |
Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Cadherins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Radiation Tolerance; Snail Family Transcription Factors; Survivin; Vascular Endothelial Growth Factor A; X-Linked Inhibitor of Apoptosis Protein; Zinc Finger E-box-Binding Homeobox 1 | 2020 |
CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Quinazolines; Signal Transduction | 2021 |
Flashback Foreword: Erlotinib and Gemcitabine in Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2023 |